Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Multiple Sclerosis

  Free Subscription


Articles published in Mult Scler

Retrieve available abstracts of 691 articles:
HTML format



Single Articles


    May 2020
  1. WANG FM, Davis MF, Briggs FB
    Predicting self-reported depression after the onset of multiple sclerosis using genetic and non-genetic factors.
    Mult Scler. 2020 May 18:1352458520921073. doi: 10.1177/1352458520921073.
    PubMed     Abstract available


  2. VALBURG C, Sonti A, Stern JN, Najjar S, et al
    Dietary factors in experimental autoimmune encephalomyelitis and multiple sclerosis: A comprehensive review.
    Mult Scler. 2020 May 14:1352458520923955. doi: 10.1177/1352458520923955.
    PubMed     Abstract available


  3. KILJAN S, Preziosa P, Jonkman LE, van de Berg WD, et al
    Cortical axonal loss is associated with both gray matter demyelination and white matter tract pathology in progressive multiple sclerosis: Evidence from a combined MRI-histopathology study.
    Mult Scler. 2020 May 11:1352458520918978. doi: 10.1177/1352458520918978.
    PubMed     Abstract available


  4. GHARAKHANLOU R, Wesselmann L, Rademacher A, Lampit A, et al
    Exercise training and cognitive performance in persons with multiple sclerosis: A systematic review and multilevel meta-analysis of clinical trials.
    Mult Scler. 2020 May 11:1352458520917935. doi: 10.1177/1352458520917935.
    PubMed     Abstract available


  5. LUNEMANN JD, Diaz-Diaz J, Stankoff B, Young C, et al
    Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019).
    Mult Scler. 2020 May 4:1352458520918377. doi: 10.1177/1352458520918377.
    PubMed     Abstract available


  6. BOSE G, Thebault S, Rush CA, Atkins HL, et al
    Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective.
    Mult Scler. 2020 May 4:1352458520917936. doi: 10.1177/1352458520917936.
    PubMed     Abstract available


  7. LAMBE J, Saidha S, Bermel RA
    Optical coherence tomography and multiple sclerosis: Update on clinical application and role in clinical trials.
    Mult Scler. 2020;26:624-639.
    PubMed     Abstract available


    April 2020
  8. FOX E, Lovett-Racke AE, Gormley M, Liu Y, et al
    A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
    Mult Scler. 2020 Apr 30:1352458520918375. doi: 10.1177/1352458520918375.
    PubMed     Abstract available


  9. KALB R, Brown TR, Coote S, Costello K, et al
    Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course.
    Mult Scler. 2020 Apr 23:1352458520915629. doi: 10.1177/1352458520915629.
    PubMed     Abstract available


  10. AHRABIAN D, Neill L, Bell R, Leary SM, et al
    Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
    Mult Scler. 2020 Apr 16:1352458519855725. doi: 10.1177/1352458519855725.
    PubMed     Abstract available


  11. FILIPPATOU AG, Lambe J, Sotirchos ES, Fitzgerald KC, et al
    Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis.
    Mult Scler. 2020 Apr 16:1352458519900942. doi: 10.1177/1352458519900942.
    PubMed     Abstract available


  12. UHER T, McComb M, Galkin S, Srpova B, et al
    Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.
    Mult Scler. 2020 Apr 7:1352458520912379. doi: 10.1177/1352458520912379.
    PubMed     Abstract available


  13. YUSUF F, Wijnands JM, Kingwell E, Zhu F, et al
    Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome.
    Mult Scler. 2020 Apr 6:1352458520908163. doi: 10.1177/1352458520908163.
    PubMed     Abstract available


  14. BELBASIS L, Bellou V, Evangelou E, Tzoulaki I, et al
    Environmental factors and risk of multiple sclerosis: Findings from meta-analyses and Mendelian randomization studies.
    Mult Scler. 2020;26:397-404.
    PubMed     Abstract available


    March 2020
  15. HEALY BC, Barker L, Bakshi R, Benedict RHB, et al
    Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis.
    Mult Scler. 2020 Mar 31:1352458520913439. doi: 10.1177/1352458520913439.
    PubMed     Abstract available


  16. TREMLETT H, Marrie RA
    The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities.
    Mult Scler. 2020 Mar 31:1352458520914844. doi: 10.1177/1352458520914844.
    PubMed     Abstract available


  17. MOTL RW, Sandroff BM, Benedict RH, Hubbard EM, et al
    Do subcortical gray matter volumes and aerobic capacity account for cognitive-motor coupling in multiple sclerosis?
    Mult Scler. 2020 Mar 31:1352458520914822. doi: 10.1177/1352458520914822.
    PubMed     Abstract available


  18. DEMORTIERE S, Rico A, Maarouf A, Boutiere C, et al
    Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912637. doi: 10.1177/1352458520912637.
    PubMed     Abstract available


  19. JACOBS BM, Giovannoni G, Cuzick J, Dobson R, et al
    Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors.
    Mult Scler. 2020 Mar 23:1352458520907901. doi: 10.1177/1352458520907901.
    PubMed     Abstract available


  20. DADAR M, Narayanan S, Arnold DL, Collins DL, et al
    Conversion of diffusely abnormal white matter to focal lesions is linked to progression in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912172. doi: 10.1177/1352458520912172.
    PubMed     Abstract available


  21. OTURAI DB, Bach Sondergaard H, Koch-Henriksen N, Andersen C, et al
    Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912500. doi: 10.1177/1352458520912500.
    PubMed     Abstract available


  22. PEREZ T, Rico A, Boutiere C, Maarouf A, et al
    Comparison of rituximab originator (MabThera((R))) to biosimilar (Truxima((R))) in patients with multiple sclerosis.
    Mult Scler. 2020 Mar 17:1352458520912170. doi: 10.1177/1352458520912170.
    PubMed     Abstract available


  23. SOLOMON AJ, Pettigrew R, Naismith RT, Chahin S, et al
    Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria.
    Mult Scler. 2020 Mar 12:1352458520910496. doi: 10.1177/1352458520910496.
    PubMed     Abstract available


  24. BERTOLI M, Tecchio F
    Fatigue in multiple sclerosis: Does the functional or structural damage prevail?
    Mult Scler. 2020 Mar 12:1352458520912175. doi: 10.1177/1352458520912175.
    PubMed     Abstract available


  25. DALGAS U, Hvid LG, Kwakkel G, Motl RW, et al
    Moving exercise research in multiple sclerosis forward (the MoXFo initiative): Developing consensus statements for research.
    Mult Scler. 2020 Mar 12:1352458520910360. doi: 10.1177/1352458520910360.
    PubMed     Abstract available


  26. NG HS, Kingwell E, Zhu F, Zhang T, et al
    Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study.
    Mult Scler. 2020 Mar 6:1352458520910500. doi: 10.1177/1352458520910500.
    PubMed     Abstract available


  27. ABDEL-MANNAN O, Cortese R, Wassmer E, Hemingway C, et al
    Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction?
    Mult Scler. 2020 Mar 3:1352458520910361. doi: 10.1177/1352458520910361.
    PubMed     Abstract available


    February 2020
  28. POVOLO CA, Reid JN, Shariff SZ, Welk B, et al
    Concussion in adolescence and the risk of multiple sclerosis: A retrospective cohort study.
    Mult Scler. 2020 Feb 24:1352458520908037. doi: 10.1177/1352458520908037.
    PubMed     Abstract available


  29. FONDERICO M, Biagioli T, Lanzilao L, Bellinvia A, et al
    Prognostic role of intrathecal IgM synthesis in multiple sclerosis: Results from a clinical series.
    Mult Scler. 2020 Feb 24:1352458520907913. doi: 10.1177/1352458520907913.
    PubMed     Abstract available


  30. HORISBERGER A, Pantazou V, Cuendet G, Ribi C, et al
    ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2020 Feb 21:1352458519895449. doi: 10.1177/1352458519895449.
    PubMed     Abstract available


  31. BIGAUT K, Lambert C, Kremer L, Lebrun C, et al
    Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders.
    Mult Scler. 2020 Feb 20:1352458520906995. doi: 10.1177/1352458520906995.
    PubMed     Abstract available


  32. MAHLANZA TD, Manieri MC, Klawiter EC, Solomon AJ, et al
    Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosis.
    Mult Scler. 2020 Feb 17:1352458520904545. doi: 10.1177/1352458520904545.
    PubMed     Abstract available


  33. SERRA A, Petzold A
    Can stability of visual fixation be a measure for disability in multiple sclerosis?
    Mult Scler. 2020 Feb 7:1352458520903296. doi: 10.1177/1352458520903296.
    PubMed    


  34. SHEEHY CK, Bensinger ES, Romeo A, Rani L, et al
    Fixational microsaccades: A quantitative and objective measure of disability in multiple sclerosis.
    Mult Scler. 2020 Feb 7:1352458519894712. doi: 10.1177/1352458519894712.
    PubMed     Abstract available


  35. BSTEH G, Berger T
    Commentary on "Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis".
    Mult Scler. 2020 Feb 7:1352458520904546. doi: 10.1177/1352458520904546.
    PubMed    


  36. SON M, McEwan L, Ubaidat M, Bovell K, et al
    Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
    Mult Scler. 2020 Feb 7:1352458519900961. doi: 10.1177/1352458519900961.
    PubMed     Abstract available


  37. BISTROM M, Hultdin J, Andersen O, Alonso-Magdalena L, et al
    Leptin levels are associated with multiple sclerosis risk.
    Mult Scler. 2020 Feb 7:1352458520905033. doi: 10.1177/1352458520905033.
    PubMed     Abstract available


  38. BOUVET L, Chassard D
    Is neuraxial anesthesia not associated with increased risk of post-partum relapses in multiple sclerosis? More precise assessment is required.
    Mult Scler. 2020 Feb 5:1352458519898344. doi: 10.1177/1352458519898344.
    PubMed    


  39. MARIOTTINI A, Filippini S, Innocenti C, Forci B, et al
    Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Feb 3:1352458520902392. doi: 10.1177/1352458520902392.
    PubMed     Abstract available


  40. ABSINTA M, Ontaneda D
    Controversial association between leptomeningeal enhancement and demyelinated cortical lesions in multiple sclerosis.
    Mult Scler. 2020;26:135-136.
    PubMed    


    January 2020
  41. CHARABATI M, Donkers SJ, Kirkland MC, Osborne LC, et al
    A critical analysis of helminth immunotherapy in multiple sclerosis.
    Mult Scler. 2020 Jan 23:1352458519899040. doi: 10.1177/1352458519899040.
    PubMed     Abstract available


  42. PALOTAI M, Cavallari M, Healy BC, Guttmann CR, et al
    A novel classification of fatigue in multiple sclerosis based on longitudinal assessments.
    Mult Scler. 2020 Jan 23:1352458519898112. doi: 10.1177/1352458519898112.
    PubMed     Abstract available


  43. BENEDICT RH, Pol J, Yasin F, Hojnacki D, et al
    Recovery of cognitive function after relapse in multiple sclerosis.
    Mult Scler. 2020 Jan 23:1352458519898108. doi: 10.1177/1352458519898108.
    PubMed     Abstract available


  44. CHITNIS T, Prat A
    A roadmap to precision medicine for multiple sclerosis.
    Mult Scler. 2020 Jan 22:1352458519881558. doi: 10.1177/1352458519881558.
    PubMed     Abstract available


  45. BOSE G, Freedman MS
    Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment.
    Mult Scler. 2020 Jan 22:1352458519887324. doi: 10.1177/1352458519887324.
    PubMed     Abstract available


  46. MYCKO MP, Baranzini SE
    microRNA and exosome profiling in multiple sclerosis.
    Mult Scler. 2020 Jan 22:1352458519879303. doi: 10.1177/1352458519879303.
    PubMed     Abstract available


  47. VOSKUHL RR
    The effect of sex on multiple sclerosis risk and disease progression.
    Mult Scler. 2020 Jan 22:1352458519892491. doi: 10.1177/1352458519892491.
    PubMed     Abstract available


  48. PATSOPOULOS NA, De Jager PL
    Genetic and gene expression signatures in multiple sclerosis.
    Mult Scler. 2020 Jan 22:1352458519898332. doi: 10.1177/1352458519898332.
    PubMed     Abstract available


  49. BHARGAVA P, Anthony D
    Metabolomics in multiple sclerosis disease course and progression.
    Mult Scler. 2020 Jan 22:1352458519876020. doi: 10.1177/1352458519876020.
    PubMed     Abstract available


  50. KISTER I, Kantarci OH
    Multiple Sclerosis Severity Score: Concept and applications.
    Mult Scler. 2020 Jan 22:1352458519880125. doi: 10.1177/1352458519880125.
    PubMed     Abstract available


  51. CARNERO CONTENTTI E, Giachello S, Correale J
    Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients.
    Mult Scler. 2020 Jan 21:1352458519898590. doi: 10.1177/1352458519898590.
    PubMed     Abstract available


  52. SRPOVA B, Uher T, Hrnciarova T, Barro C, et al
    Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis.
    Mult Scler. 2020 Jan 21:1352458519901272. doi: 10.1177/1352458519901272.
    PubMed     Abstract available


  53. CORTESE R, Tur C, Prados F, Schneider T, et al
    Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis.
    Mult Scler. 2020 Jan 21:1352458519900971. doi: 10.1177/1352458519900971.
    PubMed     Abstract available


  54. MCDONELL J, Costello K, Laurson-Doube J, Rijke N, et al
    World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application.
    Mult Scler. 2020 Jan 16:1352458519898340. doi: 10.1177/1352458519898340.
    PubMed     Abstract available


  55. SALTER A, Fox RJ, Tyry T, Cutter G, et al
    New applications for independent activities of daily living in measuring disability in multiple sclerosis.
    Mult Scler. 2020 Jan 14:1352458519898591. doi: 10.1177/1352458519898591.
    PubMed     Abstract available


    December 2019
  56. CROUSE DL, Foroughi I, Gupta N
    Neighbourhood environments and the risk of hospital admission for cardiometabolic and mental health comorbidities in multiple sclerosis: A population cohort analysis using linked administrative data.
    Mult Scler. 2019 Dec 20:1352458519895985. doi: 10.1177/1352458519895985.
    PubMed     Abstract available


  57. COULOUME L, Barbin L, Leray E, Wiertlewski S, et al
    High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice.
    Mult Scler. 2019 Dec 17:1352458519894713. doi: 10.1177/1352458519894713.
    PubMed     Abstract available


  58. KALKERS NF, Galan I, Kerbrat A, Tacchino A, et al
    Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries.
    Mult Scler. 2019 Dec 17:1352458519895450. doi: 10.1177/1352458519895450.
    PubMed     Abstract available


  59. KVISTAD SAS, Lehmann AK, Trovik LH, Kristoffersen EK, et al
    Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway.
    Mult Scler. 2019 Dec 13:1352458519893926. doi: 10.1177/1352458519893926.
    PubMed     Abstract available


  60. HOLTON KF, Kirkland AE
    Moving past antioxidant supplementation for the dietary treatment of multiple sclerosis.
    Mult Scler. 2019 Dec 11:1352458519893925. doi: 10.1177/1352458519893925.
    PubMed     Abstract available


  61. RAHNAMA'I MS
    Neuromodulation for functional bladder disorders in patients with multiple sclerosis.
    Mult Scler. 2019 Dec 9:1352458519894714. doi: 10.1177/1352458519894714.
    PubMed     Abstract available


  62. BISECCO A, Capuano R, Caiazzo G, d'Ambrosio A, et al
    Regional changes in thalamic shape and volume are related to cognitive performance in multiple sclerosis.
    Mult Scler. 2019 Dec 3:1352458519892552. doi: 10.1177/1352458519892552.
    PubMed     Abstract available


  63. HARDY TA
    Regulatory B cells: The key to post-alemtuzumab rebound phenomena in multiple sclerosis?
    Mult Scler. 2019;25:1945-1946.
    PubMed    


    November 2019
  64. GONZALEZ CAMPO C, Salamone PC, Rodriguez-Arriagada N, Richter F, et al
    Fatigue in multiple sclerosis is associated with multimodal interoceptive abnormalities.
    Mult Scler. 2019 Nov 28:1352458519888881. doi: 10.1177/1352458519888881.
    PubMed     Abstract available


  65. COHEN JA, Trojano M, Mowry EM, Uitdehaag BM, et al
    Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment.
    Mult Scler. 2019 Nov 28:1352458519892555. doi: 10.1177/1352458519892555.
    PubMed     Abstract available


  66. WALLACH AI, Waltz M, Casper TC, Aaen G, et al
    Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline.
    Mult Scler. 2019 Nov 28:1352458519891984. doi: 10.1177/1352458519891984.
    PubMed     Abstract available


  67. LI CMF, Hung PS, Chu PP, Tohyama S, et al
    Trigeminal neuralgia associated with multiple sclerosis: A multimodal assessment of brainstem plaques and response to Gamma Knife radiosurgery.
    Mult Scler. 2019 Nov 26:1352458519886070. doi: 10.1177/1352458519886070.
    PubMed     Abstract available


  68. KIM JE, Park SH, Han K, Kim HJ, et al
    Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea.
    Mult Scler. 2019 Nov 21:1352458519888609. doi: 10.1177/1352458519888609.
    PubMed     Abstract available


  69. BRANDSTADTER R, Fabian M, Leavitt VM, Krieger S, et al
    Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis.
    Mult Scler. 2019 Nov 19:1352458519881760. doi: 10.1177/1352458519881760.
    PubMed     Abstract available


  70. BAETGE SJ, Filser M, Renner A, Ullrich S, et al
    On the validity of single tests, two-test combinations and the full Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in detecting patients with cognitive impairment.
    Mult Scler. 2019 Nov 19:1352458519887897. doi: 10.1177/1352458519887897.
    PubMed     Abstract available


  71. ZURAWSKI J, Tauhid S, Chu R, Khalid F, et al
    7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions.
    Mult Scler. 2019 Nov 12:1352458519885106. doi: 10.1177/1352458519885106.
    PubMed     Abstract available


  72. PELLEGRINI F, Copetti M, Sormani MP, Bovis F, et al
    Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling.
    Mult Scler. 2019 Nov 5:1352458519887343. doi: 10.1177/1352458519887343.
    PubMed     Abstract available


  73. CORDANI C, Valsasina P, Preziosa P, Meani A, et al
    Action observation training promotes motor improvement and modulates functional network dynamic connectivity in multiple sclerosis.
    Mult Scler. 2019 Nov 5:1352458519887332. doi: 10.1177/1352458519887332.
    PubMed     Abstract available


  74. COLLORONE S, Cawley N, Grussu F, Prados F, et al
    Reduced neurite density in the brain and cervical spinal cord in relapsing-remitting multiple sclerosis: A NODDI study.
    Mult Scler. 2019 Nov 4:1352458519885107. doi: 10.1177/1352458519885107.
    PubMed     Abstract available


  75. MILO R, Korczyn AD, Manouchehri N, Stuve O, et al
    The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis.
    Mult Scler. 2019 Nov 4:1352458519886943. doi: 10.1177/1352458519886943.
    PubMed     Abstract available


  76. NAISMITH RT, Wolinsky JS, Wundes A, LaGanke C, et al
    Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Mult Scler. 2019 Nov 4:1352458519881761. doi: 10.1177/1352458519881761.
    PubMed     Abstract available


  77. KUHLE J, Plavina T, Barro C, Disanto G, et al
    Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
    Mult Scler. 2019 Nov 4:1352458519885613. doi: 10.1177/1352458519885613.
    PubMed     Abstract available


  78. VAN WIJMEERSCH B, Singer BA, Boster A, Broadley S, et al
    Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
    Mult Scler. 2019 Nov 1:1352458519881759. doi: 10.1177/1352458519881759.
    PubMed     Abstract available


  79. MOSTERT JP, De Keyser J
    Response to Grech et al.: FLOUX-PMS study sample considerations.
    Mult Scler. 2019;25:1820-1821.
    PubMed    


  80. GRECH LB, Butler E, Stuckey S, Hester R, et al
    Letter to the editor: FLOUX-PMS study sample considerations.
    Mult Scler. 2019;25:1819-1820.
    PubMed    


    October 2019
  81. RYAN JM, Fortune J, Stennett A, Kilbride C, et al
    Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial.
    Mult Scler. 2019 Oct 31:1352458519886231. doi: 10.1177/1352458519886231.
    PubMed     Abstract available


  82. LEAVITT VM, Riley CS, De Jager PL, Bloom S, et al
    eSupport: Feasibility trial of telehealth support group participation to reduce loneliness in multiple sclerosis.
    Mult Scler. 2019 Oct 31:1352458519884241. doi: 10.1177/1352458519884241.
    PubMed     Abstract available


  83. ZHOU Y, Claflin SB, Stankovich J, van der Mei I, et al
    Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
    Mult Scler. 2019 Oct 31:1352458519881994. doi: 10.1177/1352458519881994.
    PubMed     Abstract available


  84. CLARKE MA, Samaraweera AP, Falah Y, Pitiot A, et al
    Single Test to ARrive at Multiple Sclerosis (STAR-MS) diagnosis: A prospective pilot study assessing the accuracy of the central vein sign in predicting multiple sclerosis in cases of diagnostic uncertainty.
    Mult Scler. 2019 Oct 31:1352458519882282. doi: 10.1177/1352458519882282.
    PubMed     Abstract available


  85. BSTEH G, Berek K, Hegen H, Teuchner B, et al
    Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.
    Mult Scler. 2019 Oct 31:1352458519882279. doi: 10.1177/1352458519882279.
    PubMed     Abstract available


  86. WOJCIK CM, Beier M, Costello K, DeLuca J, et al
    Computerized neuropsychological assessment devices in multiple sclerosis: A systematic review.
    Mult Scler. 2019 Oct 22:1352458519879094. doi: 10.1177/1352458519879094.
    PubMed     Abstract available


  87. CHITNIS T
    Serum NFL levels should be used to monitor multiple sclerosis evolution - Commentary.
    Mult Scler. 2019 Oct 18:1352458519880471. doi: 10.1177/1352458519880471.
    PubMed    


  88. MYHR KM, Torkildsen O
    Serum NFL levels should be used to monitor multiple sclerosis evolution - No.
    Mult Scler. 2019 Oct 18:1352458519872891. doi: 10.1177/1352458519872891.
    PubMed    


  89. LEPPERT D, Kuhle J
    Serum NfL levels should be used to monitor multiple sclerosis evolution - Yes.
    Mult Scler. 2019 Oct 18:1352458519872921. doi: 10.1177/1352458519872921.
    PubMed    


  90. JOHANSSON S, Ytterberg C, Gottberg K, Holmqvist LW, et al
    Participation in social/lifestyle activities in people with multiple sclerosis: Changes across 10 years and predictors of sustained participation.
    Mult Scler. 2019 Oct 17:1352458519881991. doi: 10.1177/1352458519881991.
    PubMed     Abstract available


  91. MANEZ-MIRO JU, Martinez-Fernandez R, Del Alamo M, Pineda-Pardo JA, et al
    Focused ultrasound thalamotomy for multiple sclerosis-associated tremor.
    Mult Scler. 2019 Oct 16:1352458519861597. doi: 10.1177/1352458519861597.
    PubMed     Abstract available


  92. JAKIMOVSKI D, Zivadinov R, Ramanthan M, Hagemeier J, et al
    Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
    Mult Scler. 2019 Oct 15:1352458519881428. doi: 10.1177/1352458519881428.
    PubMed     Abstract available


  93. DAMASCENO A, Pimentel-Silva LR, Damasceno BP, Cendes F, et al
    Cognitive trajectories in relapsing-remitting multiple sclerosis: A longitudinal 6-year study.
    Mult Scler. 2019 Oct 11:1352458519878685. doi: 10.1177/1352458519878685.
    PubMed     Abstract available


  94. BIANCHI A, Ciccarelli O
    Daclizumab-induced encephalitis in multiple sclerosis.
    Mult Scler. 2019;25:1557-1559.
    PubMed    


  95. IGHANI M, Jonas S, Izbudak I, Choi S, et al
    No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis.
    Mult Scler. 2019 Oct 1:1352458519876037. doi: 10.1177/1352458519876037.
    PubMed     Abstract available


  96. GRYTTEN N, Myhr KM, Celius EG, Benjaminsen E, et al
    Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study.
    Mult Scler. 2019 Oct 1:1352458519877244. doi: 10.1177/1352458519877244.
    PubMed     Abstract available


  97. ZECCA C, Bovis F, Novi G, Capobianco M, et al
    Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
    Mult Scler. 2019 Oct 1:1352458519872889. doi: 10.1177/1352458519872889.
    PubMed     Abstract available


  98. MACARON G, Ontaneda D
    Clinical commentary on "Warts and all: Fingolimod and unusual HPV associated lesions".
    Mult Scler. 2019;25:1550-1552.
    PubMed    


  99. BERGER JR
    PML with dimethyl fumarate-No role for natalizumab?
    Mult Scler. 2019;25:1686-1687.
    PubMed    


    September 2019
  100. PALOTAI M, Guttmann CR
    Brain anatomical correlates of fatigue in multiple sclerosis.
    Mult Scler. 2019 Sep 19:1352458519876032. doi: 10.1177/1352458519876032.
    PubMed     Abstract available


  101. MAGGI P, Absinta M, Sati P, Perrotta G, et al
    The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study.
    Mult Scler. 2019 Sep 19:1352458519876031. doi: 10.1177/1352458519876031.
    PubMed     Abstract available


  102. MARRIE RA, Tremlett H, Kingwell E, Schaffer SA, et al
    Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study.
    Mult Scler. 2019 Sep 13:1352458519876038. doi: 10.1177/1352458519876038.
    PubMed     Abstract available


  103. VAN GEEL F, Veldkamp R, Severijns D, Dalgas U, et al
    Day-to-day reliability, agreement and discriminative validity of measuring walking-related performance fatigability in persons with multiple sclerosis.
    Mult Scler. 2019 Sep 9:1352458519872465. doi: 10.1177/1352458519872465.
    PubMed     Abstract available


  104. BRANDSTADTER R, Katz Sand I, Sumowski JF
    Beyond rehabilitation: A prevention model of reserve and brain maintenance in multiple sclerosis.
    Mult Scler. 2019;25:1372-1378.
    PubMed     Abstract available


  105. WEBER E, Goverover Y, DeLuca J
    Beyond cognitive dysfunction: Relevance of ecological validity of neuropsychological tests in multiple sclerosis.
    Mult Scler. 2019;25:1412-1419.
    PubMed     Abstract available


    August 2019
  106. PALOTAI M, Cavallari M, Koubiyr I, Morales Pinzon A, et al
    Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression.
    Mult Scler. 2019 Aug 16:1352458519869185. doi: 10.1177/1352458519869185.
    PubMed     Abstract available


  107. FAMBIATOS A, Jokubaitis V, Horakova D, Kubala Havrdova E, et al
    Risk of secondary progressive multiple sclerosis: A longitudinal study.
    Mult Scler. 2019 Aug 9:1352458519868990. doi: 10.1177/1352458519868990.
    PubMed     Abstract available


  108. PISA M, Ratti F, Vabanesi M, Radaelli M, et al
    Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography.
    Mult Scler. 2019 Aug 8:1352458519861603. doi: 10.1177/1352458519861603.
    PubMed     Abstract available


  109. SIVAKOLUNDU DK, West KL, Maruthy GB, Zuppichini M, et al
    Reduced arterial compliance along the cerebrovascular tree predicts cognitive slowing in multiple sclerosis: Evidence for a neurovascular uncoupling hypothesis.
    Mult Scler. 2019 Aug 2:1352458519866605. doi: 10.1177/1352458519866605.
    PubMed     Abstract available


  110. HERRANZ E, Louapre C, Treaba CA, Govindarajan ST, et al
    Profiles of cortical inflammation in multiple sclerosis by (11)C-PBR28 MR-PET and 7 Tesla imaging.
    Mult Scler. 2019 Aug 1:1352458519867320. doi: 10.1177/1352458519867320.
    PubMed     Abstract available


  111. MCGINLEY MP, Cola PA, Fox RJ, Cohen JA, et al
    Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies.
    Mult Scler. 2019 Aug 1:1352458519867314. doi: 10.1177/1352458519867314.
    PubMed     Abstract available


  112. BOVE R, Rankin K, Lin C, Zhao C, et al
    Effect of assisted reproductive technology on multiple sclerosis relapses: Case series and meta-analysis.
    Mult Scler. 2019 Aug 1:1352458519865118. doi: 10.1177/1352458519865118.
    PubMed     Abstract available


  113. BEECHAM AH, Amezcua L, Chinea A, Manrique CP, et al
    The genetic diversity of multiple sclerosis risk among Hispanic and African American populations living in the United States.
    Mult Scler. 2019 Aug 1:1352458519863764. doi: 10.1177/1352458519863764.
    PubMed     Abstract available


  114. KILLESTEIN J, van Oosten B
    Emerging safety issues in alemtuzumab-treated MS patients.
    Mult Scler. 2019;25:1206-1208.
    PubMed    


    July 2019
  115. SOTIRCHOS ES, Filippatou A, Fitzgerald KC, Salama S, et al
    Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning.
    Mult Scler. 2019 Jul 31:1352458519864928. doi: 10.1177/1352458519864928.
    PubMed     Abstract available


  116. SCHWEHR NA, Kuntz KM, Butler M, Enns EA, et al
    Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis.
    Mult Scler. 2019 Jul 29:1352458519866613. doi: 10.1177/1352458519866613.
    PubMed     Abstract available


  117. CAMPBELL JA, Simpson S Jr, Ahmad H, Taylor BV, et al
    Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data.
    Mult Scler. 2019 Jul 26:1352458519861270. doi: 10.1177/1352458519861270.
    PubMed     Abstract available


  118. LARSSON D, Akerfeldt T, Carlson K, Burman J, et al
    Intrathecal immunoglobulins and neurofilament light after autologous haematopoietic stem cell transplantation for multiple sclerosis.
    Mult Scler. 2019 Jul 26:1352458519863983. doi: 10.1177/1352458519863983.
    PubMed     Abstract available


  119. PRAVATA E, Valsasina P, Gobbi C, Zecca C, et al
    Influence of CNS T2-focal lesions on cervical cord atrophy and disability in multiple sclerosis.
    Mult Scler. 2019 Jul 26:1352458519865989. doi: 10.1177/1352458519865989.
    PubMed     Abstract available


  120. CALLESEN J, Cattaneo D, Brincks J, Kjeldgaard Jorgensen ML, et al
    How do resistance training and balance and motor control training affect gait performance and fatigue impact in people with multiple sclerosis? A randomized controlled multi-center study.
    Mult Scler. 2019 Jul 24:1352458519865740. doi: 10.1177/1352458519865740.
    PubMed     Abstract available


  121. BRIGGS FB, Hill E
    Estimating the prevalence of multiple sclerosis using 56.6 million electronic health records from the United States.
    Mult Scler. 2019 Jul 24:1352458519864681. doi: 10.1177/1352458519864681.
    PubMed     Abstract available


  122. HACOHEN Y, Brownlee W, Mankad K, Chong WK', et al
    Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort.
    Mult Scler. 2019 Jul 18:1352458519863781. doi: 10.1177/1352458519863781.
    PubMed     Abstract available


  123. CAMARA-LEMARROY CR, Silva C, Greenfield J, Liu WQ, et al
    Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity.
    Mult Scler. 2019 Jul 18:1352458519863133. doi: 10.1177/1352458519863133.
    PubMed     Abstract available


  124. WARNKE C, Hartung HP
    Challenging a concept: Pulsed treatment regimen-No risk of PML?
    Mult Scler. 2019;25:1076-1078.
    PubMed    


  125. GEREVINI S, Capra R, Bertoli D, Sottini A, et al
    Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy.
    Mult Scler. 2019;25:1196-1201.
    PubMed     Abstract available


  126. PREZIOSA P, Rocca MA, Filippi M
    PET is necessary to make the next step forward in understanding MS pathophysiology - No.
    Mult Scler. 2019;25:1088-1090.
    PubMed    


  127. BODINI B, Stankoff B
    PET is necessary to make the next step forward in understanding MS pathophysiology - Yes.
    Mult Scler. 2019;25:1086-1087.
    PubMed    


  128. COMBES B, Kerbrat A, Ferre JC, Callot V, et al
    Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetisation transfer ratio study.
    Mult Scler. 2019;25:1113-1123.
    PubMed     Abstract available


  129. KANG Y, Gauthier SA
    PET is necessary to make the next step forward in understanding MS pathophysiology - Commentary.
    Mult Scler. 2019;25:1090-1091.
    PubMed    


    June 2019
  130. DE LOTT LB, Zerafa S, Shedden K, Dunietz GL, et al
    Multiple sclerosis relapse risk in the postoperative period: Effects of invasive surgery and anesthesia.
    Mult Scler. 2019 Jun 25:1352458519860304. doi: 10.1177/1352458519860304.
    PubMed     Abstract available


  131. INEICHEN BV, Moridi T, Granberg T, Piehl F, et al
    Rituximab treatment for multiple sclerosis.
    Mult Scler. 2019 Jun 25:1352458519858604. doi: 10.1177/1352458519858604.
    PubMed     Abstract available


  132. LEAVITT VM, Brandstadter R, Fabian M, Katz Sand I, et al
    Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis.
    Mult Scler. 2019 Jun 24:1352458519860319. doi: 10.1177/1352458519860319.
    PubMed     Abstract available


  133. PERONI S, Sorosina M, Malhotra S, Clarelli F, et al
    A pharmacogenetic study implicates NINJ2 in the response to Interferon-beta in multiple sclerosis.
    Mult Scler. 2019 Jun 21:1352458519851428. doi: 10.1177/1352458519851428.
    PubMed     Abstract available


  134. MARCK CH, das Nair R, Grech LB, Borland R, et al
    Modifiable risk factors for poor health outcomes in multiple sclerosis: The urgent need for research to maximise smoking cessation success.
    Mult Scler. 2019 Jun 20:1352458519858730. doi: 10.1177/1352458519858730.
    PubMed     Abstract available


  135. FUCHS TA, Benedict RH, Wilding G, Wojcik C, et al
    Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis.
    Mult Scler. 2019 Jun 20:1352458519858605. doi: 10.1177/1352458519858605.
    PubMed     Abstract available


  136. CHATAWAY J, Weir CJ, Fox RJ
    The FLUOX-PMS trial: Underestimating the challenge in progressive multiple sclerosis trials.
    Mult Scler. 2019 Jun 20:1352458519856985. doi: 10.1177/1352458519856985.
    PubMed    


  137. CAMBRON M, Mostert J, D'Hooghe M, Nagels G, et al
    Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial.
    Mult Scler. 2019 Jun 20:1352458519843051. doi: 10.1177/1352458519843051.
    PubMed     Abstract available


  138. SPRENGER T, Kappos L, Radue EW, Gaetano L, et al
    Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide.
    Mult Scler. 2019 Jun 14:1352458519855722. doi: 10.1177/1352458519855722.
    PubMed     Abstract available


  139. GABR RE, Coronado I, Robinson M, Sujit SJ, et al
    Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale study.
    Mult Scler. 2019 Jun 13:1352458519856843. doi: 10.1177/1352458519856843.
    PubMed     Abstract available


  140. KLINEOVA S, Brandstadter R, Fabian MT, Sand IK, et al
    Psychological resilience is linked to motor strength and gait endurance in early multiple sclerosis.
    Mult Scler. 2019 Jun 7:1352458519852725. doi: 10.1177/1352458519852725.
    PubMed     Abstract available


  141. BROWN JWL, Prados Carrasco F, Eshaghi A, Sudre CH, et al
    Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab.
    Mult Scler. 2019 Jun 6:1352458519852093. doi: 10.1177/1352458519852093.
    PubMed     Abstract available


  142. MARRIE RA, Dufault B, Tyry T, Cutter GR, et al
    Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis.
    Mult Scler. 2019 Jun 4:1352458519852722. doi: 10.1177/1352458519852722.
    PubMed     Abstract available


  143. STAMPANONI BASSI M, Iezzi E, Buttari F, Gilio L, et al
    Obesity worsens central inflammation and disability in multiple sclerosis.
    Mult Scler. 2019 Jun 4:1352458519853473. doi: 10.1177/1352458519853473.
    PubMed     Abstract available


  144. MESCHERIAKOVA JY, Verkerk J, Amin N, Uitterlinden AG, et al
    Response to Vilarino-Guell et al.
    Mult Scler. 2019;25:1013-1015.
    PubMed    


  145. SCALFARI A
    MS progression is predominantly driven by age-related mechanisms - YES.
    Mult Scler. 2019;25:902-904.
    PubMed    


  146. MCGINLEY M, Ontaneda D
    MS progression is predominantly driven by age-related mechanisms - NO.
    Mult Scler. 2019;25:904-906.
    PubMed    


  147. ZEYDAN B, Kantarci OH
    MS progression is predominantly driven by age-related mechanisms - Commentary.
    Mult Scler. 2019;25:906-908.
    PubMed    


    May 2019
  148. AKGUN K, Ziemssen T
    Response to Hyun J.W. et al. "Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis".
    Mult Scler. 2019 May 30:1352458519854263. doi: 10.1177/1352458519854263.
    PubMed    


  149. PELLEGRINI F, Copetti M, Bovis F, Cheng D, et al
    A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis.
    Mult Scler. 2019 May 30:1352458519849513. doi: 10.1177/1352458519849513.
    PubMed     Abstract available


  150. ARROYO R, Bury DP, Guo JD, Margolin DH, et al
    Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
    Mult Scler. 2019 May 30:1352458519849796. doi: 10.1177/1352458519849796.
    PubMed     Abstract available


  151. MOBERG JY, Laursen B, Thygesen LC, Magyari M, et al
    Reproductive history of the Danish multiple sclerosis population: A register-based study.
    Mult Scler. 2019 May 30:1352458519851245. doi: 10.1177/1352458519851245.
    PubMed     Abstract available


  152. CAPONE F, Collorone S, Cortese R, Di Lazzaro V, et al
    Fatigue in multiple sclerosis: The role of thalamus.
    Mult Scler. 2019 May 29:1352458519851247. doi: 10.1177/1352458519851247.
    PubMed     Abstract available


  153. MCCOMBE PA
    Women who contributed to past research in multiple sclerosis.
    Mult Scler. 2019 May 28:1352458519846101. doi: 10.1177/1352458519846101.
    PubMed     Abstract available


  154. MARRIE RA
    Recognizing the diversity gap in multiple sclerosis.
    Mult Scler. 2019 May 28:1352458519850070. doi: 10.1177/1352458519850070.
    PubMed    


  155. AHRWEILLER K, Rousseau C, Le Page E, Bajeux E, et al
    Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis.
    Mult Scler. 2019 May 16:1352458519848090. doi: 10.1177/1352458519848090.
    PubMed     Abstract available


  156. MURPHY OC, Kwakyi O, Iftikhar M, Zafar S, et al
    Alterations in the retinal vasculature occur in multiple sclerosis and exhibit novel correlations with disability and visual function measures.
    Mult Scler. 2019 May 16:1352458519845116. doi: 10.1177/1352458519845116.
    PubMed     Abstract available


  157. PUGLIATTI M
    Changes in the sex ratio are a good indicator of changes in multiple sclerosis incidence - Commentary.
    Mult Scler. 2019 May 15:1352458519845114. doi: 10.1177/1352458519845114.
    PubMed    


  158. KOPP TI, Blinkenberg M, Chalmer TA, Petersen T, et al
    Predictors of treatment outcome in patients with paediatric onset multiple sclerosis.
    Mult Scler. 2019 May 13:1352458519846100. doi: 10.1177/1352458519846100.
    PubMed     Abstract available


  159. CONTE A, Gianni C, Belvisi D, Cortese A, et al
    Deep grey matter involvement and altered sensory gating in multiple sclerosis.
    Mult Scler. 2019 May 13:1352458519845287. doi: 10.1177/1352458519845287.
    PubMed     Abstract available


  160. FITZGERALD KC, Salter A, Tyry T, Fox RJ, et al
    Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis.
    Mult Scler. 2019 May 13:1352458519845836. doi: 10.1177/1352458519845836.
    PubMed     Abstract available


  161. MOSS BP, Cohen JA
    The emergence of follow-on disease-modifying therapies for multiple sclerosis.
    Mult Scler. 2019 May 10:1352458519845106. doi: 10.1177/1352458519845106.
    PubMed     Abstract available


  162. TUR C, Grussu F, Prados F, Charalambous T, et al
    A multi-shell multi-tissue diffusion study of brain connectivity in early multiple sclerosis.
    Mult Scler. 2019 May 10:1352458519845105. doi: 10.1177/1352458519845105.
    PubMed     Abstract available


  163. FALET JR, Deshmukh S, Al-Jassim A, Sigler G, et al
    The neurologist's role in disabling multiple sclerosis: A qualitative study of patient and care provider perspectives.
    Mult Scler. 2019 May 10:1352458519845107. doi: 10.1177/1352458519845107.
    PubMed     Abstract available


  164. FAZEKAS F
    Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - Commentary.
    Mult Scler. 2019;25:770-771.
    PubMed    


  165. SOLOMON AJ
    Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - Yes.
    Mult Scler. 2019;25:766-768.
    PubMed    


  166. BROWNLEE WJ
    Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - No.
    Mult Scler. 2019;25:768-770.
    PubMed    


  167. TRIPLETT J, Vijayan S, Prince R, Kermode A, et al
    Dimethyl fumarate-associated transient bone marrow oedema syndrome.
    Mult Scler. 2019;25:876-879.
    PubMed     Abstract available


  168. ROSATO R, Testa S, Bertolotto A, Scavelli F, et al
    eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54.
    Mult Scler. 2019;25:856-866.
    PubMed     Abstract available


  169. GOODIN DS, Reder AT, Traboulsee AL, Li DK, et al
    Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.
    Mult Scler. 2019;25:837-847.
    PubMed     Abstract available


  170. DUROZARD P, Maarouf A, Boutiere C, Ruet A, et al
    Efficacy of rituximab in refractory RRMS.
    Mult Scler. 2019;25:828-836.
    PubMed     Abstract available


    April 2019
  171. PHELPS R, Winston JA, Wynn D, Habek M, et al
    Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.
    Mult Scler. 2019 Apr 15:1352458519841829. doi: 10.1177/1352458519841829.
    PubMed     Abstract available


  172. BARLETTA VT, Herranz E, Treaba CA, Ouellette R, et al
    Evidence of diffuse cerebellar neuroinflammation in multiple sclerosis by (11)C-PBR28 MR-PET.
    Mult Scler. 2019 Apr 11:1352458519843048. doi: 10.1177/1352458519843048.
    PubMed     Abstract available


  173. VUKUSIC S, Coyle PK, Jurgensen S, Truffinet P, et al
    Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.
    Mult Scler. 2019 Apr 10:1352458519843055. doi: 10.1177/1352458519843055.
    PubMed     Abstract available


  174. BROWN JWL, Chowdhury A, Kanber B, Prados Carrasco F, et al
    Magnetisation transfer ratio abnormalities in primary and secondary progressive multiple sclerosis.
    Mult Scler. 2019 Apr 8:1352458519841810. doi: 10.1177/1352458519841810.
    PubMed     Abstract available


  175. BANWELL B
    Are children with multiple sclerosis really "old" adults.
    Mult Scler. 2019 Apr 4:1352458519841505. doi: 10.1177/1352458519841505.
    PubMed    


  176. BARTELS F, Nobis K, Cooper G, Wendel E, et al
    Childhood multiple sclerosis is associated with reduced brain volumes at first clinical presentation and brain growth failure.
    Mult Scler. 2019 Apr 4:1352458519829698. doi: 10.1177/1352458519829698.
    PubMed     Abstract available


  177. LAVIE C, Rollot F, Durand-Dubief F, Marignier R, et al
    Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.
    Mult Scler. 2019;25:591-600.
    PubMed     Abstract available


  178. BUCK D, Andlauer TF, Igl W, Wicklein EM, et al
    Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
    Mult Scler. 2019;25:565-573.
    PubMed     Abstract available


  179. HYUN JW, Huh SY, Shin HJ, Woodhall M, et al
    Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis.
    Mult Scler. 2019;25:585-590.
    PubMed     Abstract available


  180. ZELEK WM, Watkins LM, Howell OW, Evans R, et al
    Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59.
    Mult Scler. 2019;25:523-531.
    PubMed     Abstract available


  181. MANOUSAKI D, Richards JB
    Vitamin D deficiency is an etiological factor for MS - Yes.
    Mult Scler. 2019;25:637-639.
    PubMed    


  182. LANGER-GOULD A, Lucas RM
    Vitamin D deficiency is an etiological factor for MS - No.
    Mult Scler. 2019;25:639-641.
    PubMed    


  183. WILLIAMS T, Chataway J
    Immune-mediated encephalitis with daclizumab: The final nail.
    Mult Scler. 2019;25:753-754.
    PubMed     Abstract available


  184. THOUVENOT E, Hinsinger G, Demattei C, Uygunoglu U, et al
    Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome.
    Mult Scler. 2019;25:669-677.
    PubMed     Abstract available


    March 2019
  185. HYUN JW, Kim Y, Kim G, Kim SH, et al
    Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.
    Mult Scler. 2019 Mar 26:1352458519840757. doi: 10.1177/1352458519840757.
    PubMed     Abstract available


  186. BOONSTRA FM, Noffs G, Perera T, Jokubaitis VG, et al
    Functional neuroplasticity in response to cerebello-thalamic injury underpins the clinical presentation of tremor in multiple sclerosis.
    Mult Scler. 2019 Mar 25:1352458519837706. doi: 10.1177/1352458519837706.
    PubMed     Abstract available


  187. BAGNATO F, Franco G, Ye F, Fan R, et al
    Selective inversion recovery quantitative magnetization transfer imaging: Toward a 3 T clinical application in multiple sclerosis.
    Mult Scler. 2019 Mar 25:1352458519833018. doi: 10.1177/1352458519833018.
    PubMed     Abstract available


  188. D'AMBROSIO A, Valsasina P, Gallo A, De Stefano N, et al
    Reduced dynamics of functional connectivity and cognitive impairment in multiple sclerosis.
    Mult Scler. 2019 Mar 19:1352458519837707. doi: 10.1177/1352458519837707.
    PubMed     Abstract available


  189. RUSSO CV, Sacca F, Paternoster M, Buonomo AR, et al
    Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2019 Mar 18:1352458518813110. doi: 10.1177/1352458518813110.
    PubMed    


  190. STRAUDI S, Manfredini F, Lamberti N, Martinuzzi C, et al
    Robot-assisted gait training is not superior to intensive overground walking in multiple sclerosis with severe disability (the RAGTIME study): A randomized controlled trial.
    Mult Scler. 2019 Mar 4:1352458519833901. doi: 10.1177/1352458519833901.
    PubMed     Abstract available


  191. BARANZINI SE
    Insights into microbiome research 6: The role of consortia in studying the role of microbes in health and disease.
    Mult Scler. 2019;25:336-337.
    PubMed     Abstract available


  192. WATTJES MP, Killestein J
    Imaging of meningeal inflammation should become part of the routine MRI protocol - No.
    Mult Scler. 2019;25:331-333.
    PubMed    


  193. ABSINTA M, Reich DS
    Imaging of meningeal inflammation should become part of the routine MRI protocol - Yes.
    Mult Scler. 2019;25:330-331.
    PubMed    


  194. DEISENHAMMER F, Jank M, Lauren A, Sjodin A, et al
    Prediction of natalizumab anti-drug antibodies persistency.
    Mult Scler. 2019;25:392-398.
    PubMed     Abstract available


  195. ROCCA MA, Riccitelli GC, Meani A, Pagani E, et al
    Cognitive reserve, cognition, and regional brain damage in MS: A 2 -year longitudinal study.
    Mult Scler. 2019;25:372-381.
    PubMed     Abstract available


  196. AL-LOUZI O, Sotirchos ES, Vidal-Jordana A, Beh SC, et al
    Characteristics of morphologic macular abnormalities in neuroimmunology practice.
    Mult Scler. 2019;25:361-371.
    PubMed     Abstract available


    February 2019
  197. PALMER AJ, van der Mei I, Taylor BV, Clarke PM, et al
    Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia.
    Mult Scler. 2019 Feb 26:1352458519831213. doi: 10.1177/1352458519831213.
    PubMed     Abstract available


  198. URRU SA, Antonelli A, Sechi GM
    Prevalence of multiple sclerosis in Sardinia: A systematic cross-sectional multi-source survey.
    Mult Scler. 2019 Feb 22:1352458519828600. doi: 10.1177/1352458519828600.
    PubMed     Abstract available


  199. PORTACCIO E, Amato MP
    Breastfeeding and post-partum relapses in multiple sclerosis patients.
    Mult Scler. 2019 Feb 22:1352458519830588. doi: 10.1177/1352458519830588.
    PubMed     Abstract available


  200. JAKIMOVSKI D, Ramanathan M, Weinstock-Guttman B, Bergsland N, et al
    Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.
    Mult Scler. 2019 Feb 13:1352458519828667. doi: 10.1177/1352458519828667.
    PubMed     Abstract available


  201. SOTIRCHOS ES, Gonzalez-Caldito N, Dewey BE, Fitzgerald KC, et al
    Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
    Mult Scler. 2019 Feb 11:1352458519826364. doi: 10.1177/1352458519826364.
    PubMed     Abstract available


  202. CICERO CE, Patti F, Lo Fermo S, Giuliano L, et al
    Lack of association between Toxocara canis and multiple sclerosis: A population-based case-control study.
    Mult Scler. 2019 Feb 11:1352458518825394. doi: 10.1177/1352458518825394.
    PubMed    


  203. LEFEUVRE JA, Guy JR, Luciano NJ, Ha SK, et al
    The spectrum of spinal cord lesions in a primate model of multiple sclerosis.
    Mult Scler. 2019 Feb 7:1352458518822408. doi: 10.1177/1352458518822408.
    PubMed     Abstract available


  204. NICOLETTI CG, Monteleone F, Marfia GA, Usiello A, et al
    Oral D-Aspartate enhances synaptic plasticity reserve in progressive multiple sclerosis.
    Mult Scler. 2019 Feb 7:1352458519828294. doi: 10.1177/1352458519828294.
    PubMed     Abstract available


  205. RAIMO S, Spitaleri D, Trojano L, Santangelo G, et al
    Apathy as a herald of cognitive changes in multiple sclerosis: A 2-year follow-up study.
    Mult Scler. 2019 Feb 7:1352458519828296. doi: 10.1177/1352458519828296.
    PubMed     Abstract available


  206. PLANCHE V, Su JH, Mournet S, Saranathan M, et al
    White-matter-nulled MPRAGE at 7T reveals thalamic lesions and atrophy of specific thalamic nuclei in multiple sclerosis.
    Mult Scler. 2019 Feb 7:1352458519828297. doi: 10.1177/1352458519828297.
    PubMed     Abstract available


  207. CHARD DT
    Commentary on Al Hussona et al. 'New-onset seizures as a sole clinical presentation of multiple sclerosis'.
    Mult Scler. 2019;25:298-299.
    PubMed     Abstract available


  208. BARANZINI SE
    Insights into microbiome research 5: Mapping is first but function must come next.
    Mult Scler. 2019;25:193-195.
    PubMed     Abstract available


  209. HELLWIG K
    We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - No.
    Mult Scler. 2019;25:189-190.
    PubMed    


  210. ALVAREZ E, Mowry EM
    We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Yes.
    Mult Scler. 2019;25:187-188.
    PubMed    


  211. BOVE R
    We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Commentary.
    Mult Scler. 2019;25:190-192.
    PubMed    


  212. HEDSTROM AK
    Smoking and its interaction with genetics in MS etiology.
    Mult Scler. 2019;25:180-186.
    PubMed     Abstract available


  213. BSTEH G, Hegen H, Ladstatter F, Berek K, et al
    Change of olfactory function as a marker of inflammatory activity and disability progression in MS.
    Mult Scler. 2019;25:267-274.
    PubMed     Abstract available


  214. BOVIS F, De Stefano N, Steinerman JR, Knappertz V, et al
    Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS.
    Mult Scler. 2019;25:217-223.
    PubMed     Abstract available


    January 2019
  215. STORK L, Bruck W, von Gottberg P, Pulkowski U, et al
    Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis.
    Mult Scler. 2019 Jan 18:1352458518819098. doi: 10.1177/1352458518819098.
    PubMed     Abstract available


  216. CORDANI C, Meani A, Esposito F, Valsasina P, et al
    Imaging correlates of hand motor performance in multiple sclerosis: A multiparametric structural and functional MRI study.
    Mult Scler. 2019 Jan 18:1352458518822145. doi: 10.1177/1352458518822145.
    PubMed     Abstract available


  217. VALENCIA-SANCHEZ C, Goodman BP, Carter JL, Wingerchuk DM, et al
    The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations.
    Mult Scler. 2019 Jan 18:1352458518823482. doi: 10.1177/1352458518823482.
    PubMed     Abstract available


  218. VAN MUNSTER CE, Kaya L, Obura M, Kalkers NF, et al
    Minimal clinically important difference of improvement on the Arm Function in Multiple Sclerosis Questionnaire (AMSQ).
    Mult Scler. 2019 Jan 18:1352458518823489. doi: 10.1177/1352458518823489.
    PubMed     Abstract available


  219. BARIN L, Kamm CP, Salmen A, Dressel H, et al
    How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.
    Mult Scler. 2019 Jan 18:1352458518823955. doi: 10.1177/1352458518823955.
    PubMed     Abstract available


  220. MARRODAN M, Alessandro L, Farez MF, Correale J, et al
    The role of infections in multiple sclerosis.
    Mult Scler. 2019 Jan 14:1352458518823940. doi: 10.1177/1352458518823940.
    PubMed     Abstract available


  221. PAGANI E, Rocca MA, De Meo E, Horsfield MA, et al
    Structural connectivity in multiple sclerosis and modeling of disconnection.
    Mult Scler. 2019 Jan 9:1352458518820759. doi: 10.1177/1352458518820759.
    PubMed     Abstract available


  222. JAKIMOVSKI D, Benedict RH, Marr K, Gandhi S, et al
    Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients.
    Mult Scler. 2019 Jan 9:1352458518819608. doi: 10.1177/1352458518819608.
    PubMed     Abstract available


  223. FUCHS TA, Wojcik C, Wilding GE, Pol J, et al
    Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis.
    Mult Scler. 2019 Jan 7:1352458518820272. doi: 10.1177/1352458518820272.
    PubMed     Abstract available


  224. BARANZINI SE
    Insights into microbiome research 4: The computational analysis.
    Mult Scler. 2019;25:21-22.
    PubMed     Abstract available


  225. THOMPSON AJ, Antel J, Carroll WB, Geurts J, et al
    MSJ 2019 - Editorial comment.
    Mult Scler. 2019;25:4-5.
    PubMed    


  226. PITT D, Ponath G
    Astrocytes play a crucial role in the formation and evolution of MS lesions - Yes.
    Mult Scler. 2019;25:15-17.
    PubMed    


  227. KERLERO DE ROSBO N
    Astrocytes play a crucial role in the formation and evolution of MS lesions - No.
    Mult Scler. 2019;25:17-19.
    PubMed    


  228. VIJAYASINGHAM L, Viswanathan S
    A call for more research and global collaboration in South-East Asia to address challenges of DMT access and MS management in the region.
    Mult Scler. 2019;25:130-131.
    PubMed    


  229. PATEL VP, Feinstein A
    The link between depression and performance on the Symbol Digit Modalities Test: Mechanisms and clinical significance.
    Mult Scler. 2019;25:118-121.
    PubMed     Abstract available


  230. MAZZOLA MA, Raheja R, Regev K, Beynon V, et al
    Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells.
    Mult Scler. 2019;25:63-71.
    PubMed     Abstract available


  231. QUINTANA FJ
    Astrocytes play a crucial role in the formation and evolution of MS lesions - Commentary.
    Mult Scler. 2019;25:19-20.
    PubMed    


    December 2018
  232. HOGEL H, Rissanen E, Barro C, Matilainen M, et al
    Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
    Mult Scler. 2018 Dec 20:1352458518819380. doi: 10.1177/1352458518819380.
    PubMed     Abstract available


  233. SATCHIDANAND N, Drake A, Smerbeck A, Hojnacki D, et al
    Dalfampridine benefits ambulation but not cognition in multiple sclerosis.
    Mult Scler. 2018 Dec 19:1352458518815795. doi: 10.1177/1352458518815795.
    PubMed     Abstract available


  234. ELLIOTT C, Wolinsky JS, Hauser SL, Kappos L, et al
    Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
    Mult Scler. 2018 Dec 19:1352458518814117. doi: 10.1177/1352458518814117.
    PubMed     Abstract available


  235. MATTHEWS L
    Clinical commentary on 'Relapsing remitting multiple sclerosis in progressive external ophthalmoplegia: A report of two cases'.
    Mult Scler. 2018 Dec 17:1352458518816621. doi: 10.1177/1352458518816621.
    PubMed    


  236. PATEL KR, Karaa A, Mateen FJ
    Relapsing remitting multiple sclerosis in progressive external ophthalmoplegia: A report of two cases.
    Mult Scler. 2018 Dec 17:1352458518800794. doi: 10.1177/1352458518800794.
    PubMed     Abstract available


  237. POURCHER V, Todesco E, Dubois C, Pallier C, et al
    False hepatitis B and C viral serologies in patients with multiple sclerosis receiving high-dose biotin.
    Mult Scler. 2018 Dec 11:1352458518818294. doi: 10.1177/1352458518818294.
    PubMed    


  238. BSTEH G, Algrang L, Hegen H, Auer M, et al
    Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.
    Mult Scler. 2018 Dec 3:1352458518816614. doi: 10.1177/1352458518816614.
    PubMed     Abstract available


  239. VAUGHN CB, Kavak KS, Dwyer MG, Bushra A, et al
    Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium.
    Mult Scler. 2018 Dec 3:1352458518816619. doi: 10.1177/1352458518816619.
    PubMed     Abstract available


    November 2018
  240. BSTEH G, Berek K, Hegen H, Teuchner B, et al
    Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration.
    Mult Scler. 2018 Nov 22:1352458518814113. doi: 10.1177/1352458518814113.
    PubMed     Abstract available


  241. WOJCIK CM, Rao SM, Schembri AJ, Drake AS, et al
    Necessity of technicians for computerized neuropsychological assessment devices in multiple sclerosis.
    Mult Scler. 2018 Nov 22:1352458518813287. doi: 10.1177/1352458518813287.
    PubMed     Abstract available


  242. WALLECZEK NK, Frommlet F, Bsteh G, Eggers C, et al
    Month-of-birth-effect in multiple sclerosis in Austria.
    Mult Scler. 2018 Nov 22:1352458518810924. doi: 10.1177/1352458518810924.
    PubMed     Abstract available


  243. SEGAL BM
    Enhancing natural killer cells is beneficial in multiple sclerosis - Commentary.
    Mult Scler. 2018 Nov 13:1352458518809296. doi: 10.1177/1352458518809296.
    PubMed    


  244. LIU Q, Shi FD
    Enhancing natural killer cells is beneficial in multiple sclerosis - No.
    Mult Scler. 2018 Nov 13:1352458518799591. doi: 10.1177/1352458518799591.
    PubMed    


  245. LARONI A
    Enhancing natural killer cells is beneficial in multiple sclerosis - Yes.
    Mult Scler. 2018 Nov 13:1352458518800776. doi: 10.1177/1352458518800776.
    PubMed    


  246. RAATS J, Lamers I, Baert I, Willekens B, et al
    Cognitive-motor interference in persons with multiple sclerosis during five upper limb motor tasks with different complexity.
    Mult Scler. 2018 Nov 12:1352458518808194. doi: 10.1177/1352458518808194.
    PubMed     Abstract available


  247. FOX EJ, Markowitz C, Applebee A, Montalban X, et al
    Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
    Mult Scler. 2018 Nov 12:1352458518808189. doi: 10.1177/1352458518808189.
    PubMed     Abstract available


  248. LUIJTEN MA, Eekhout I, D'Hooghe M, Uitdehaag BM, et al
    Development of the Arm Function in Multiple Sclerosis Questionnaire-Short Form (AMSQ-SF): A static 10-item version.
    Mult Scler. 2018 Nov 9:1352458518808197. doi: 10.1177/1352458518808197.
    PubMed     Abstract available


  249. LAMERS I, Feys P
    Patient reported outcome measures of upper limb function in multiple sclerosis: A critical overview.
    Mult Scler. 2018 Nov 9:1352458518809294. doi: 10.1177/1352458518809294.
    PubMed    


  250. HYUN JW, Kim Y, Kim G, Kim SH, et al
    Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
    Mult Scler. 2018 Nov 7:1352458518810261. doi: 10.1177/1352458518810261.
    PubMed     Abstract available


  251. ACHIRON A, Sarova-Pinhas I, Magalashvili D, Stern Y, et al
    Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapy.
    Mult Scler. 2018 Nov 1:1352458518809903. doi: 10.1177/1352458518809903.
    PubMed     Abstract available


  252. HOBART J, Bowen A, Pepper G, Crofts H, et al
    International consensus on quality standards for brain health-focused care in multiple sclerosis.
    Mult Scler. 2018 Nov 1:1352458518809326. doi: 10.1177/1352458518809326.
    PubMed     Abstract available


  253. HEALY BC, Zurawski J, Gonzalez CT, Chitnis T, et al
    Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis.
    Mult Scler. 2018 Nov 1:1352458518810159. doi: 10.1177/1352458518810159.
    PubMed     Abstract available


  254. PEETERS LM, van Munster CE, Van Wijmeersch B, Bruyndonckx R, et al
    Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done!
    Mult Scler. 2018 Nov 1:1352458518807076. doi: 10.1177/1352458518807076.
    PubMed     Abstract available


    October 2018
  255. FARRELL R
    Clinical commentary on "De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine".
    Mult Scler. 2018 Oct 30:1352458518810661. doi: 10.1177/1352458518810661.
    PubMed    


  256. PANICUCCI E, Cohen M, Bourg V, Rocher F, et al
    De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine.
    Mult Scler. 2018 Oct 30:1352458518790379. doi: 10.1177/1352458518790379.
    PubMed     Abstract available


  257. DOBSON R
    Clinical commentary on 'Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: a note of caution'.
    Mult Scler. 2018 Oct 25:1352458518807053. doi: 10.1177/1352458518807053.
    PubMed    


  258. FEIGE J, Salmhofer H, Hecker C, Kunz AB, et al
    Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: A note of caution.
    Mult Scler. 2018 Oct 25:1352458518807059. doi: 10.1177/1352458518807059.
    PubMed     Abstract available


  259. AHMAD H, van der Mei I, Taylor BV, Lucas RM, et al
    Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Oct 23:1352458518806103. doi: 10.1177/1352458518806103.
    PubMed     Abstract available


  260. SOELBERG SORENSEN P, Giovannoni G, Montalban X, Thalheim C, et al
    The Multiple Sclerosis Care Unit.
    Mult Scler. 2018 Oct 23:1352458518807082. doi: 10.1177/1352458518807082.
    PubMed     Abstract available


  261. ROTSTEIN DL, Cortese M, Fung TT, Chitnis T, et al
    Diet quality and risk of multiple sclerosis in two cohorts of US women.
    Mult Scler. 2018 Oct 23:1352458518807061. doi: 10.1177/1352458518807061.
    PubMed     Abstract available


  262. STROBER L, DeLuca J, Benedict RH, Jacobs A, et al
    Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.
    Mult Scler. 2018 Oct 18:1352458518808204. doi: 10.1177/1352458518808204.
    PubMed     Abstract available


  263. BURROWS DJ, McGown A, Jain SA, De Felice M, et al
    Animal models of multiple sclerosis: From rodents to zebrafish.
    Mult Scler. 2018 Oct 15:1352458518805246. doi: 10.1177/1352458518805246.
    PubMed     Abstract available


  264. DUBUISSON N, Marta M, Gnanapavan S, Turner B, et al
    Inclusion criteria used in trials of people with progressive multiple sclerosis.
    Mult Scler. 2018 Oct 15:1352458518803769. doi: 10.1177/1352458518803769.
    PubMed    


  265. GRAF J, Ringelstein M, Lepka K, Schaller J, et al
    Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.
    Mult Scler. 2018 Oct 11:1352458518771276. doi: 10.1177/1352458518771276.
    PubMed     Abstract available


  266. WILLIS MD, Hope-Gill B, Flood-Page P, Joseph F, et al
    Sarcoidosis following alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2018 Oct 11:1352458518790391. doi: 10.1177/1352458518790391.
    PubMed     Abstract available


  267. PFEUFFER S
    Sarcoidosis following alemtuzumab treatment: Autoimmunity mediated by T cells and interferon-gamma.
    Mult Scler. 2018 Oct 11:1352458518804124. doi: 10.1177/1352458518804124.
    PubMed    


  268. CONWAY BL, Zeydan B, Uygunoglu U, Novotna M, et al
    Age is a critical determinant in recovery from multiple sclerosis relapses.
    Mult Scler. 2018 Oct 10:1352458518800815. doi: 10.1177/1352458518800815.
    PubMed     Abstract available


  269. KALB R, Beier M, Benedict RH, Charvet L, et al
    Recommendations for cognitive screening and management in multiple sclerosis care.
    Mult Scler. 2018 Oct 10:1352458518803785. doi: 10.1177/1352458518803785.
    PubMed     Abstract available


  270. VILARINO-GUELL C, Encarnacion M, Bernales CQ, Sadovnick AD, et al
    Analysis of Canadian multiple sclerosis patients does not support a role for FKBP6 in disease.
    Mult Scler. 2018 Oct 9:1352458518803789. doi: 10.1177/1352458518803789.
    PubMed    


  271. KREMER D, Akkermann R, Kury P, Dutta R, et al
    Current advancements in promoting remyelination in multiple sclerosis.
    Mult Scler. 2018 Oct 1:1352458518800827. doi: 10.1177/1352458518800827.
    PubMed     Abstract available


  272. TATEO F, Grassivaro F, Ermani M, Puthenparampil M, et al
    PM2.5 levels strongly associate with multiple sclerosis prevalence in the Province of Padua, Veneto Region, North-East Italy.
    Mult Scler. 2018 Oct 1:1352458518803273. doi: 10.1177/1352458518803273.
    PubMed     Abstract available


    September 2018
  273. BOSE G, Atkins HL, Bowman M, Freedman MS, et al
    Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis.
    Mult Scler. 2018 Sep 25:1352458518802544. doi: 10.1177/1352458518802544.
    PubMed     Abstract available


  274. MIN M, Spelman T, Lugaresi A, Boz C, et al
    Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.
    Mult Scler. 2018 Sep 20:1352458518798147. doi: 10.1177/1352458518798147.
    PubMed     Abstract available


  275. LAVORGNA L, Brigo F, Moccia M, Leocani L, et al
    e-Health and multiple sclerosis: An update.
    Mult Scler. 2018 Sep 19:1352458518799629. doi: 10.1177/1352458518799629.
    PubMed     Abstract available


  276. ANTONAZZO IC, Poluzzi E, Forcesi E, Riise T, et al
    Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System.
    Mult Scler. 2018 Sep 19:1352458518799598. doi: 10.1177/1352458518799598.
    PubMed     Abstract available


  277. ROMMER PS, Eichstadt K, Ellenberger D, Flachenecker P, et al
    Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry.
    Mult Scler. 2018 Sep 19:1352458518799580. doi: 10.1177/1352458518799580.
    PubMed     Abstract available


  278. O'GRADY KP, Dula AN, Lyttle BD, Thompson LM, et al
    Glutamate-sensitive imaging and evaluation of cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Sep 19:1352458518799583. doi: 10.1177/1352458518799583.
    PubMed     Abstract available


  279. BENJAMIN LA
    A tale of two demyelinating diseases and Zika virus.
    Mult Scler. 2018 Sep 18:1352458518799584. doi: 10.1177/1352458518799584.
    PubMed    


    August 2018
  280. VAN ROSSUM JA, Killestein J, Villar LM, Riskind PN, et al
    gMS-Classifier1 does not predict disability progression in multiple sclerosis.
    Mult Scler. 2018 Aug 31:1352458518798048. doi: 10.1177/1352458518798048.
    PubMed    


  281. VAN MUNSTER CE, D'Souza M, Steinheimer S, Kamm CP, et al
    Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis.
    Mult Scler. 2018 Aug 31:1352458518796690. doi: 10.1177/1352458518796690.
    PubMed     Abstract available


  282. O'MAHONY J, Marrie RA, Laporte A, Bar-Or A, et al
    Pediatric-onset multiple sclerosis is associated with reduced parental health-related quality of life and family functioning.
    Mult Scler. 2018 Aug 30:1352458518796676. doi: 10.1177/1352458518796676.
    PubMed     Abstract available


  283. BOVE R, Bevan C, Crabtree E, Zhao C, et al
    Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis.
    Mult Scler. 2018 Aug 24:1352458518793527. doi: 10.1177/1352458518793527.
    PubMed     Abstract available


  284. NICHOLAS RS, Han E, Raffel J, Chataway J, et al
    Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials.
    Mult Scler. 2018 Aug 24:1352458518794063. doi: 10.1177/1352458518794063.
    PubMed     Abstract available


  285. SKJERBAEK AG, Boesen F, Petersen T, Rasmussen PV, et al
    Can we trust self-reported walking distance when determining EDSS scores in patients with multiple sclerosis? The Danish MS hospitals rehabilitation study.
    Mult Scler. 2018 Aug 20:1352458518795416. doi: 10.1177/1352458518795416.
    PubMed     Abstract available


  286. ANDERSEN C, Sondergaard HB, Bang Oturai D, Laursen JH, et al
    Alcohol consumption in adolescence is associated with a lower risk of multiple sclerosis in a Danish cohort.
    Mult Scler. 2018 Aug 20:1352458518795418. doi: 10.1177/1352458518795418.
    PubMed     Abstract available


  287. GAUZZI MC
    Vitamin D-binding protein and multiple sclerosis: Evidence, controversies, and needs.
    Mult Scler. 2018 Aug 16:1352458518792433. doi: 10.1177/1352458518792433.
    PubMed     Abstract available


  288. SELLEBJERG F, Royen L, Soelberg Sorensen P, Oturai AB, et al
    Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Mult Scler. 2018 Aug 16:1352458518794308. doi: 10.1177/1352458518794308.
    PubMed     Abstract available


  289. VISWANATHAN S, Wah LM
    A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia.
    Mult Scler. 2018 Aug 16:1352458518792430. doi: 10.1177/1352458518792430.
    PubMed     Abstract available


  290. SEEBACHER B, Kuisma R, Glynn A, Berger T, et al
    Effects and mechanisms of differently cued and non-cued motor imagery in people with multiple sclerosis: A randomised controlled trial.
    Mult Scler. 2018 Aug 14:1352458518795332. doi: 10.1177/1352458518795332.
    PubMed     Abstract available


  291. PIETROBONI AM, Caprioli M, Carandini T, Scarioni M, et al
    CSF beta-amyloid predicts prognosis in patients with multiple sclerosis.
    Mult Scler. 2018 Aug 7:1352458518791709. doi: 10.1177/1352458518791709.
    PubMed     Abstract available


  292. ROCCA MA, Meani A, Fumagalli S, Pagani E, et al
    Functional and structural plasticity following action observation training in multiple sclerosis.
    Mult Scler. 2018 Aug 7:1352458518792771. doi: 10.1177/1352458518792771.
    PubMed     Abstract available


  293. KUSPINAR A, Mayo NE
    Validation of the preference-based multiple sclerosis index.
    Mult Scler. 2018 Aug 2:1352458518792423. doi: 10.1177/1352458518792423.
    PubMed     Abstract available


  294. TOMASSINI V, Fanelli F, Prosperini L, Cerqua R, et al
    Predicting the profile of increasing disability in multiple sclerosis.
    Mult Scler. 2018 Aug 2:1352458518790397. doi: 10.1177/1352458518790397.
    PubMed     Abstract available


  295. PETERSEN ER, Sondergaard HB, Laursen JH, Olsson AG, et al
    Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis.
    Mult Scler. 2018 Aug 2:1352458518791753. doi: 10.1177/1352458518791753.
    PubMed     Abstract available


  296. DI STADIO A, Ralli M
    Inner ear involvement in multiple sclerosis: An underestimated condition?
    Mult Scler. 2018;24:1264-1265.
    PubMed    


  297. BHAN A, Jacobsen C, Myhr KM, Dalen I, et al
    Neurofilaments and 10-year follow-up in multiple sclerosis.
    Mult Scler. 2018 Aug 1:1352458518782005. doi: 10.1177/1352458518782005.
    PubMed     Abstract available


    July 2018
  298. YANG R, Dunn JF
    Multiple sclerosis disease progression: Contributions from a hypoxia-inflammation cycle.
    Mult Scler. 2018 Jul 27:1352458518791683. doi: 10.1177/1352458518791683.
    PubMed     Abstract available


  299. SACCA F, Lanzillo R, Signori A, Maniscalco GT, et al
    Determinants of therapy switch in multiple sclerosis treatment-naive patients: A real-life study.
    Mult Scler. 2018 Jul 25:1352458518790390. doi: 10.1177/1352458518790390.
    PubMed     Abstract available


  300. HYUN JW, Kim W, Huh SY, Park MS, et al
    Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome.
    Mult Scler. 2018 Jul 25:1352458518790702. doi: 10.1177/1352458518790702.
    PubMed     Abstract available


  301. HOLM HANSEN R, Hojsgaard Chow H, Sellebjerg F, Rode von Essen M, et al
    Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Jul 25:1352458518790417. doi: 10.1177/1352458518790417.
    PubMed     Abstract available


  302. COHEN JA, Comi G, Arnold DL, Bar-Or A, et al
    Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884.
    PubMed     Abstract available


  303. LIN F, Zivadinov R, Hagemeier J, Weinstock-Guttman B, et al
    Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition.
    Mult Scler. 2018 Jul 1:1352458518788218. doi: 10.1177/1352458518788218.
    PubMed     Abstract available


  304. SENDERS A, Hanes D, Bourdette D, Carson K, et al
    Impact of mindfulness-based stress reduction for people with multiple sclerosis at 8 weeks and 12 months: A randomized clinical trial.
    Mult Scler. 2018 Jul 1:1352458518786650. doi: 10.1177/1352458518786650.
    PubMed     Abstract available


  305. FISSOLO N, Cervera-Carles L, Villar Guimerans LM, Lleo A, et al
    Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis.
    Mult Scler. 2018 Jul 1:1352458518786055. doi: 10.1177/1352458518786055.
    PubMed     Abstract available


  306. OSHIMA Y, Tanimoto T, Yuji K, Tojo A, et al
    Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Mult Scler. 2018 Jul 1:1352458518786075. doi: 10.1177/1352458518786075.
    PubMed     Abstract available


  307. WIJNANDS JM, Zhu F, Kingwell E, Zhao Y, et al
    Five years before multiple sclerosis onset: Phenotyping the prodrome.
    Mult Scler. 2018 Jul 1:1352458518783662. doi: 10.1177/1352458518783662.
    PubMed     Abstract available


  308. WONG YYM, van der Vuurst de Vries RM, van Pelt ED, Ketelslegers IA, et al
    T-cell activation marker sCD27 is associated with clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes.
    Mult Scler. 2018 Jul 1:1352458518786655. doi: 10.1177/1352458518786655.
    PubMed     Abstract available


  309. KEARNEY H
    Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - No.
    Mult Scler. 2018 Jul 1:1352458518770279. doi: 10.1177/1352458518770279.
    PubMed    


  310. SASTRE-GARRIGA J
    Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Commentary.
    Mult Scler. 2018 Jul 1:1352458518783362. doi: 10.1177/1352458518783362.
    PubMed    


  311. CORTESE R, Ciccarelli O
    Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Yes.
    Mult Scler. 2018 Jul 1:1352458518778010. doi: 10.1177/1352458518778010.
    PubMed    


    June 2018
  312. MESCHERIAKOVA JY, Verkerk AJ, Amin N, Uitterlinden AG, et al
    Linkage analysis and whole exome sequencing identify a novel candidate gene in a Dutch multiple sclerosis family.
    Mult Scler. 2018 Jun 1:1352458518777202. doi: 10.1177/1352458518777202.
    PubMed     Abstract available


  313. PUTHENPARAMPIL M, Zito A, Pantano G, Federle L, et al
    Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset.
    Mult Scler. 2018 Jun 1:1352458518779951. doi: 10.1177/1352458518779951.
    PubMed     Abstract available


  314. AL HUSSONA M, Kearney H, Fisher A, Lynch J, et al
    New onset seizures as a sole clinical presentation of multiple sclerosis.
    Mult Scler. 2018 Jun 1:1352458518781994. doi: 10.1177/1352458518781994.
    PubMed     Abstract available


  315. REDDEL SW, Barnett MH, Riminton S, Dugal T, et al
    Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study.
    Mult Scler. 2018 Jun 1:1352458518783673. doi: 10.1177/1352458518783673.
    PubMed     Abstract available


  316. CHEN J, Taylor B, Palmer AJ, Kirk-Brown A, et al
    Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis.
    Mult Scler. 2018 Jun 1:1352458518781971. doi: 10.1177/1352458518781971.
    PubMed     Abstract available


  317. MANOUCHEHRINIA A, Zhu F, Piani-Meier D, Lange M, et al
    Predicting risk of secondary progression in multiple sclerosis: A nomogram.
    Mult Scler. 2018 Jun 1:1352458518783667. doi: 10.1177/1352458518783667.
    PubMed     Abstract available


  318. GALLAGHER LG, Ilango S, Wundes A, Stobbe GA, et al
    Lifetime exposure to ultraviolet radiation and the risk of multiple sclerosis in the US radiologic technologists cohort study.
    Mult Scler. 2018 Jun 1:1352458518783343. doi: 10.1177/1352458518783343.
    PubMed     Abstract available


  319. MAGALHAES S, Banwell B, Bar-Or A, Fortier I, et al
    A framework for measurement and harmonization of pediatric multiple sclerosis etiologic research studies: The Pediatric MS Tool-Kit.
    Mult Scler. 2018 Jun 1:1352458518783345. doi: 10.1177/1352458518783345.
    PubMed     Abstract available


  320. ALVES-LEON SV, Lima MDR, Nunes PCG, Chimelli LMC, et al
    Zika virus found in brain tissue of a multiple sclerosis patient undergoing an acute disseminated encephalomyelitis-like episode.
    Mult Scler. 2018 Jun 1:1352458518781992. doi: 10.1177/1352458518781992.
    PubMed     Abstract available


    May 2018
  321. FROEHLICH A, Schmidt S, Landsberg J, Bieber T, et al
    Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod.
    Mult Scler. 2018 May 1:1352458518774444. doi: 10.1177/1352458518774444.
    PubMed    


  322. NAUTA IM, Balk LJ, Sonder JM, Hulst HE, et al
    The clinical value of the patient-reported multiple sclerosis neuropsychological screening questionnaire.
    Mult Scler. 2018 May 1:1352458518777295. doi: 10.1177/1352458518777295.
    PubMed     Abstract available


  323. ROMME CHRISTENSEN J, Komori M, von Essen MR, Ratzer R, et al
    CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
    Mult Scler. 2018 May 1:1352458518774880. doi: 10.1177/1352458518774880.
    PubMed     Abstract available


  324. MILLS EA, Mao-Draayer Y
    Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.
    Mult Scler. 2018 May 1:1352458518775550. doi: 10.1177/1352458518775550.
    PubMed     Abstract available


  325. VAN DER VUURST DE VRIES RM, Wong YYM, Mescheriakova JY, van Pelt ED, et al
    High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
    Mult Scler. 2018 May 1:1352458518775303. doi: 10.1177/1352458518775303.
    PubMed     Abstract available


  326. SCHEE JP, Viswanathan S
    Pure spinal multiple sclerosis: A possible novel entity within the multiple sclerosis disease spectrum.
    Mult Scler. 2018 May 1:1352458518775912. doi: 10.1177/1352458518775912.
    PubMed     Abstract available


  327. BOESEN MS, Koch-Henriksen N, Thygesen LC, Eriksson F, et al
    Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study.
    Mult Scler. 2018 May 1:1352458518771871. doi: 10.1177/1352458518771871.
    PubMed     Abstract available


  328. BAKER G, Nair KPS, Baster K, Rosato R, et al
    Reliability and acceptability of the Multiple Sclerosis Quality of Life-29 questionnaire in an English-speaking cohort.
    Mult Scler. 2018 May 1:1352458518776583. doi: 10.1177/1352458518776583.
    PubMed     Abstract available


  329. BEESLEY R, Anderson V, Harding KE, Joseph F, et al
    Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosis.
    Mult Scler. 2018 May 1:1352458518778007. doi: 10.1177/1352458518778007.
    PubMed    


  330. HUGOS CL, Cameron MH, Chen Z, Chen Y, et al
    A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Long-term (12-month) follow-up at one site.
    Mult Scler. 2018 May 1:1352458518775920. doi: 10.1177/1352458518775920.
    PubMed     Abstract available


  331. TSAGKAS C, Magon S, Gaetano L, Pezold S, et al
    Preferential spinal cord volume loss in primary progressive multiple sclerosis.
    Mult Scler. 2018 May 1:1352458518775006. doi: 10.1177/1352458518775006.
    PubMed     Abstract available


  332. MARANZANO J, Till C, Assemlal HE, Fonov V, et al
    Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI.
    Mult Scler. 2018 May 1:1352458518779952. doi: 10.1177/1352458518779952.
    PubMed     Abstract available


  333. BJORNEVIK K, Myhr KM, Beiske A, Bjerve KS, et al
    alpha-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.
    Mult Scler. 2018 May 1:1352458518779925. doi: 10.1177/1352458518779925.
    PubMed     Abstract available


    April 2018
  334. ALMEIDA KJ, Barreto-Soares RV, Campos-Sousa RN, Campos-Sousa MG, et al
    Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518763091. doi: 10.1177/1352458518763091.
    PubMed     Abstract available


  335. MCNICHOLAS N, Lockhart A, Yap SM, O'Connell K, et al
    New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770088. doi: 10.1177/1352458518770088.
    PubMed     Abstract available


  336. KREMER D, Kury P, Hartung HP
    ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518768770. doi: 10.1177/1352458518768770.
    PubMed     Abstract available


  337. KOBELT G, Langdon D, Jonsson L
    The effect of self-assessed fatigue and subjective cognitive impairment on work capacity: The case of multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518769837. doi: 10.1177/1352458518769837.
    PubMed     Abstract available


  338. VAVASOUR IM, Tam R, Li DK, Laule C, et al
    A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.
    Mult Scler. 2018 Apr 1:1352458518770085. doi: 10.1177/1352458518770085.
    PubMed     Abstract available


  339. MARRIE RA, Montalban X
    Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night.
    Mult Scler. 2018;24:558-562.
    PubMed    


  340. LORSCHEIDER J, Benkert P, Lienert C, Hanni P, et al
    Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518768433. doi: 10.1177/1352458518768433.
    PubMed     Abstract available


  341. SAUL A, Taylor B, Simpson S Jr, Ponsonby AL, et al
    Polymorphism in the serotonin transporter gene polymorphisms ( 5-HTTLPR) modifies the association between significant life events and depression in people with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770021. doi: 10.1177/1352458518770021.
    PubMed     Abstract available


  342. LLUFRIU S, Rocca MA, Pagani E, Riccitelli GC, et al
    Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis.
    Mult Scler. 2018 Apr 1:1352458518771838. doi: 10.1177/1352458518771838.
    PubMed     Abstract available


  343. CREARY LE, Mallempati KC, Gangavarapu S, Caillier SJ, et al
    Deconstruction of HLA-DRB1*04:01:01 and HLA-DRB1*15:01:01 class II haplotypes using next-generation sequencing in European-Americans with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770019. doi: 10.1177/1352458518770019.
    PubMed     Abstract available


  344. MCCLURG D, Bugge C, Elders A, Irshad T, et al
    Factors affecting continuation of clean intermittent catheterisation in people with multiple sclerosis: Results of the COSMOS mixed-methods study.
    Mult Scler. 2018 Apr 1:1352458518768722. doi: 10.1177/1352458518768722.
    PubMed     Abstract available


  345. WAGLEY S, Bokori-Brown M, Morcrette H, Malaspina A, et al
    Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518767327. doi: 10.1177/1352458518767327.
    PubMed     Abstract available


  346. GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan KW, et al
    Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
    Mult Scler. 2018 Apr 1:1352458518771875. doi: 10.1177/1352458518771875.
    PubMed     Abstract available


  347. GIORDANA MT, Cavalla P, Uccelli A, Laroni A, et al
    Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation.
    Mult Scler. 2018 Apr 1:1352458518763095. doi: 10.1177/1352458518763095.
    PubMed     Abstract available


  348. GIACOMINI PS
    Rebound disease in multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518772913. doi: 10.1177/1352458518772913.
    PubMed    


  349. HARMEL P, Schlunk F, Harms L
    Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report.
    Mult Scler. 2018 Apr 1:1352458517741191. doi: 10.1177/1352458517741191.
    PubMed     Abstract available


    March 2018
  350. KOENIG KA, Rao SM, Lowe MJ, Lin J, et al
    The role of the thalamus and hippocampus in episodic memory performance in patients with multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518760716. doi: 10.1177/1352458518760716.
    PubMed     Abstract available


  351. GOBEL K, Ruck T, Meuth SG
    Cytokine signaling in multiple sclerosis: Lost in translation.
    Mult Scler. 2018 Mar 1:1352458518763094. doi: 10.1177/1352458518763094.
    PubMed     Abstract available


  352. LEE JY, De Jager PL
    What is the epigenome and is it involved in multiple sclerosis?
    Mult Scler. 2018;24:268-269.
    PubMed    


  353. SILLER N, Kuhle J, Muthuraman M, Barro C, et al
    Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765666. doi: 10.1177/1352458518765666.
    PubMed     Abstract available


  354. SOWA P, Harbo HF, White NS, Celius EG, et al
    Restriction spectrum imaging of white matter and its relation to neurological disability in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765671. doi: 10.1177/1352458518765671.
    PubMed     Abstract available


  355. CORTI L, Ayrignac X, Carra Dalliere C, Charif M, et al
    Late activity rebound in non-active multiple sclerosis: A rare event.
    Mult Scler. 2018 Mar 1:1352458518765670. doi: 10.1177/1352458518765670.
    PubMed    


  356. CASTELLI L, Prosperini L, Pozzilli C
    Balance worsening associated with nabiximols in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765649. doi: 10.1177/1352458518765649.
    PubMed     Abstract available


  357. GRAETZ C, Groger A, Luessi F, Salmen A, et al
    Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541.
    PubMed     Abstract available


  358. HUA LH, Fan TH, Conway D, Thompson N, et al
    Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.
    Mult Scler. 2018 Mar 1:1352458518765656. doi: 10.1177/1352458518765656.
    PubMed     Abstract available


  359. LANZILLO R, Moccia M, Criscuolo C, Cennamo G, et al
    Optical coherence tomography angiography detects retinal vascular alterations in different phases of multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518768060. doi: 10.1177/1352458518768060.
    PubMed    


  360. VAN GEEST Q, Boeschoten RE, Keijzer MJ, Steenwijk MD, et al
    Fronto-limbic disconnection in patients with multiple sclerosis and depression.
    Mult Scler. 2018 Mar 1:1352458518767051. doi: 10.1177/1352458518767051.
    PubMed     Abstract available


  361. TOLEDANO M, Weinshenker BG, Kaufmann TJ, Parisi JE, et al
    Demographics and clinical characteristics of episodic hypothermia in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518767045. doi: 10.1177/1352458518767045.
    PubMed     Abstract available


  362. LEIBOVITCH EC, Lin CM, Billioux BJ, Graves J, et al
    Prevalence of salivary human herpesviruses in pediatric multiple sclerosis cases and controls.
    Mult Scler. 2018 Mar 1:1352458518765654. doi: 10.1177/1352458518765654.
    PubMed     Abstract available


    February 2018
  363. JAEGER S, Paul F, Scheel M, Brandt A, et al
    Multiple sclerosis-related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex.
    Mult Scler. 2018 Feb 1:1352458518758911. doi: 10.1177/1352458518758911.
    PubMed     Abstract available


  364. DE STEFANO N, Giorgio A, Tintore M, Pia Amato M, et al
    Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations.
    Mult Scler. 2018;24:214-221.
    PubMed    


  365. ROOSTAEI T, Sadaghiani S, Mashhadi R, Falahatian M, et al
    Convergent effects of a functional C3 variant on brain atrophy, demyelination, and cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Feb 1:1352458518760715. doi: 10.1177/1352458518760715.
    PubMed     Abstract available


  366. CAVALERA C, Rovaris M, Mendozzi L, Pugnetti L, et al
    Online meditation training for people with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2018 Feb 1:1352458518761187. doi: 10.1177/1352458518761187.
    PubMed     Abstract available


  367. CAMARA-LEMARROY CR, Castillo J, Sastre-Garriga J, Tintore M, et al
    Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.
    Mult Scler. 2018 Feb 1:1352458518761185. doi: 10.1177/1352458518761185.
    PubMed     Abstract available


  368. PIEHL F, Hillert J
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes.
    Mult Scler. 2018 Feb 1:1352458518757930. doi: 10.1177/1352458518757930.
    PubMed    


  369. CREE BA
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary.
    Mult Scler. 2018 Feb 1:1352458518760717. doi: 10.1177/1352458518760717.
    PubMed    


  370. WALLIN MT
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No.
    Mult Scler. 2018 Feb 1:1352458518757931. doi: 10.1177/1352458518757931.
    PubMed    


  371. BARKHOF F
    The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS - Commentary.
    Mult Scler. 2018;24:125-126.
    PubMed    


  372. PORTER B
    Commentary on "Localized pigmentation disorder after subcutaneous pegylated interferon beta 1a injection" by Coghe et al.
    Mult Scler. 2018;24:233-235.
    PubMed    


    January 2018
  373. HILVEN K, Vandebergh M, Smets I, Mallants K, et al
    Genetic basis for relapse rate in multiple sclerosis: Association with LRP2 genetic variation.
    Mult Scler. 2018 Jan 1:1352458517749894. doi: 10.1177/1352458517749894.
    PubMed     Abstract available


  374. FEUCHT N, Maier M, Lepennetier G, Pettenkofer M, et al
    Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517750009. doi: 10.1177/1352458517750009.
    PubMed     Abstract available


  375. DI STADIO A, Ralli M
    Inner ear involvement in multiple sclerosis: An underestimated condition?
    Mult Scler. 2018 Jan 1:1352458518750010. doi: 10.1177/1352458518750010.
    PubMed    


  376. DAMOTTE V, Lizee A, Tremblay M, Agrawal A, et al
    Harnessing electronic medical records to advance research on multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517747407. doi: 10.1177/1352458517747407.
    PubMed     Abstract available


  377. DE STEFANO N, Giorgio A
    Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al.
    Mult Scler. 2018 Jan 1:1352458517748476. doi: 10.1177/1352458517748476.
    PubMed    


  378. SCHIFFMANN I, Scheiderbauer J, Riemann-Lorenz K, Heesen C, et al
    Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?
    Mult Scler. 2018 Jan 1:1352458517749895. doi: 10.1177/1352458517749895.
    PubMed    


  379. SEGAL BM, Cohen JA, Antel J
    Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2017: Environmental factors, genetics, and epigenetics in MS susceptibility and clinical course.
    Mult Scler. 2018;24:4-5.
    PubMed     Abstract available


  380. TREMLETT H, Waubant E
    Gut microbiome and pediatric multiple sclerosis.
    Mult Scler. 2018;24:64-68.
    PubMed     Abstract available


  381. CASTRO K, Casaccia P
    Epigenetic modifications in brain and immune cells of multiple sclerosis patients.
    Mult Scler. 2018;24:69-74.
    PubMed     Abstract available


  382. TANKOU SK, Regev K, Healy BC, Cox LM, et al
    Investigation of probiotics in multiple sclerosis.
    Mult Scler. 2018;24:58-63.
    PubMed     Abstract available


  383. VOSKUHL RR, Sawalha AH, Itoh Y
    Sex chromosome contributions to sex differences in multiple sclerosis susceptibility and progression.
    Mult Scler. 2018;24:22-31.
    PubMed     Abstract available


  384. HAASE S, Haghikia A, Gold R, Linker RA, et al
    Dietary fatty acids and susceptibility to multiple sclerosis.
    Mult Scler. 2018;24:12-16.
    PubMed     Abstract available


  385. HARROUD A, Richards JB
    Mendelian randomization in multiple sclerosis: A causal role for vitamin D and obesity?
    Mult Scler. 2018;24:80-85.
    PubMed     Abstract available


  386. DOLEI A
    The aliens inside us: HERV-W endogenous retroviruses and multiple sclerosis.
    Mult Scler. 2018;24:42-47.
    PubMed     Abstract available


  387. CANTO E, Oksenberg JR
    Multiple sclerosis genetics.
    Mult Scler. 2018;24:75-79.
    PubMed     Abstract available


  388. WAUBANT E
    Effect of puberty on multiple sclerosis risk and course.
    Mult Scler. 2018;24:32-35.
    PubMed     Abstract available


  389. HODEL J, Bapst B, Outteryck O, Verclytte S, et al
    Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
    Mult Scler. 2018 Jan 1:1352458517750765. doi: 10.1177/1352458517750765.
    PubMed     Abstract available


  390. BOVE R, Healy BC, Musallam A, Soltany P, et al
    Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients.
    Mult Scler. 2018 Jan 1:1352458517750768. doi: 10.1177/1352458517750768.
    PubMed     Abstract available


  391. RIMKUS CM, Schoonheim MM, Steenwijk MD, Vrenken H, et al
    Gray matter networks and cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517751650. doi: 10.1177/1352458517751650.
    PubMed     Abstract available


  392. COHEN JA, Hunter SF, Brown TR, Gudesblatt M, et al
    Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
    Mult Scler. 2018 Jan 1:1352458518754716. doi: 10.1177/1352458518754716.
    PubMed     Abstract available


  393. FORD HL, Wicks CR, Stroud A, Tennant A, et al
    Psychological determinants of job retention in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458518754362. doi: 10.1177/1352458518754362.
    PubMed     Abstract available


  394. ROY S, Drake A, Fuchs T, Dwyer MG, et al
    Longitudinal personality change associated with cognitive decline in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517753720. doi: 10.1177/1352458517753720.
    PubMed     Abstract available


  395. HAUPTS MR, Spill-Askeridis P, Humpert M, Seidel D, et al
    Acute exacerbations after decades of non-active chronic multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458518754365. doi: 10.1177/1352458518754365.
    PubMed    


  396. DI IOIA M, Farina D, di Tommaso V, Travaglini D, et al
    Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517743093. doi: 10.1177/1352458517743093.
    PubMed     Abstract available


  397. MEUNIER B, Rico A, Seguier J, Boutiere C, et al
    Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
    Mult Scler. 2018 Jan 1:1352458517729766. doi: 10.1177/1352458517729766.
    PubMed     Abstract available


  398. MONTALBAN X, Gold R, Thompson AJ, Otero-Romero S, et al
    ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517751049. doi: 10.1177/1352458517751049.
    PubMed     Abstract available


  399. LAVERY AM, Collins BN, Waldman AT, Hart CN, et al
    The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk.
    Mult Scler. 2018 Jan 1:1352458518757089. doi: 10.1177/1352458518757089.
    PubMed     Abstract available


  400. BARONCINI D, Zaffaroni M, Moiola L, Lorefice L, et al
    Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.
    Mult Scler. 2018 Jan 1:1352458518754364. doi: 10.1177/1352458518754364.
    PubMed     Abstract available


    December 2017
  401. KROTH J, Ciolac D, Fleischer V, Koirala N, et al
    Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517748474. doi: 10.1177/1352458517748474.
    PubMed     Abstract available


  402. HUGOS CL, Chen Z, Chen Y, Turner AP, et al
    A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Short- and medium-term benefits.
    Mult Scler. 2017 Dec 1:1352458517745723. doi: 10.1177/1352458517745723.
    PubMed     Abstract available


  403. CALLESEN J, Richter C, Kristensen C, Sunesen I, et al
    Test-retest agreement and reliability of the Six Spot Step Test in persons with multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517745725. doi: 10.1177/1352458517745725.
    PubMed     Abstract available


  404. PEETERS LM
    Fair data for next-generation management of multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517748475. doi: 10.1177/1352458517748475.
    PubMed     Abstract available


    November 2017
  405. GRAN-RUAZ S, Mani A, O'Quinn S
    An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517739976. doi: 10.1177/1352458517739976.
    PubMed     Abstract available


  406. MANCARDI G, Sormani MP, Muraro PA, Boffa G, et al
    Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517742532. doi: 10.1177/1352458517742532.
    PubMed     Abstract available


  407. PIETROBONI AM, Dell'Arti L, Caprioli M, Scarioni M, et al
    The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients.
    Mult Scler. 2017 Nov 1:1352458517740214. doi: 10.1177/1352458517740214.
    PubMed     Abstract available


  408. MALHOTRA S, Sorosina M, Rio J, Peroni S, et al
    NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.
    Mult Scler. 2017 Nov 1:1352458517739137. doi: 10.1177/1352458517739137.
    PubMed     Abstract available


  409. MALINOVA TS, Dijkstra CD, de Vries HE
    Serotonin: A mediator of the gut-brain axis in multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517739975. doi: 10.1177/1352458517739975.
    PubMed     Abstract available


  410. ABBOUD H, Hill E, Siddiqui J, Serra A, et al
    Neuromodulation in multiple sclerosis.
    Mult Scler. 2017;23:1663-1676.
    PubMed     Abstract available


  411. FEYS P, Moumdjian L, Van Halewyck F, Wens I, et al
    Effects of an individual 12-week community-located "start-to-run" program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517740211. doi: 10.1177/1352458517740211.
    PubMed     Abstract available


  412. LOREFICE L, Fenu G, Sardu C, Frau J, et al
    Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy.
    Mult Scler. 2017 Nov 1:1352458517739989. doi: 10.1177/1352458517739989.
    PubMed     Abstract available


  413. WINGES KM, Murchison CF, Bourdette DN, Spain RI, et al
    Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort.
    Mult Scler. 2017 Nov 1:1352458517739136. doi: 10.1177/1352458517739136.
    PubMed     Abstract available


  414. UHER T, Vaneckova M, Krasensky J, Sobisek L, et al
    Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517742739. doi: 10.1177/1352458517742739.
    PubMed     Abstract available


  415. KAVALIUNAS A, Danylaite Karrenbauer V, Gyllensten H, Manouchehrinia A, et al
    Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability.
    Mult Scler. 2017 Nov 1:1352458517740212. doi: 10.1177/1352458517740212.
    PubMed     Abstract available


  416. AGIUS MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, et al
    Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
    Mult Scler. 2017 Nov 1:1352458517740641. doi: 10.1177/1352458517740641.
    PubMed     Abstract available


  417. SPITERI S, Hassa T, Claros-Salinas D, Dettmers C, et al
    Neural correlates of effort-dependent and effort-independent cognitive fatigue components in patients with multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517743090. doi: 10.1177/1352458517743090.
    PubMed     Abstract available


  418. RICCITELLI GC, Pagani E, Rodegher M, Colombo B, et al
    Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517743091. doi: 10.1177/1352458517743091.
    PubMed     Abstract available


    October 2017
  419. MOSS-MORRIS R, Norton S
    Aerobic exercise, cognitive behavioural therapy and energy conservation management for multiple sclerosis (MS) fatigue: Are three trials better than one?
    Mult Scler. 2017;23:1436-1440.
    PubMed    


  420. ZETTERBERG H, Teunissen C
    Fluid biomarkers for disease activity in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736151. doi: 10.1177/1352458517736151.
    PubMed    


  421. GIANFRANCESCO MA, Stridh P, Shao X, Rhead B, et al
    Genetic risk factors for pediatric-onset multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517733551. doi: 10.1177/1352458517733551.
    PubMed     Abstract available


  422. FOX RJ, Chataway J
    Advancing trial design in progressive multiple sclerosis.
    Mult Scler. 2017;23:1573-1578.
    PubMed     Abstract available


  423. MILLER DH, Thompson AJ
    Advancing trial design in progressive multiple sclerosis.
    Mult Scler. 2017;23:1571-1572.
    PubMed    


  424. MOCCIA M, de Stefano N, Barkhof F
    Imaging outcome measures for progressive multiple sclerosis trials.
    Mult Scler. 2017;23:1614-1626.
    PubMed     Abstract available


  425. PICHLER A, Khalil M, Langkammer C, Pinter D, et al
    The impact of vascular risk factors on brain volume and lesion load in patients with early multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736149. doi: 10.1177/1352458517736149.
    PubMed     Abstract available


  426. GLAZER CH, Tottenborg SS, Giwercman A, Brauner EV, et al
    Male factor infertility and risk of multiple sclerosis: A register-based cohort study.
    Mult Scler. 2017 Oct 1:1352458517734069. doi: 10.1177/1352458517734069.
    PubMed     Abstract available


  427. TINELLI M, Kanavos P, Efthymiadou O, Visintin E, et al
    Using IMPrESS to guide policy change in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517737388. doi: 10.1177/1352458517737388.
    PubMed     Abstract available


  428. DONADIEU M, Le Fur Y, Maarouf A, Gherib S, et al
    Metabolic counterparts of sodium accumulation in multiple sclerosis: A whole brain 23Na-MRI and fast 1H-MRSI study.
    Mult Scler. 2017 Oct 1:1352458517736146. doi: 10.1177/1352458517736146.
    PubMed     Abstract available


  429. FLEMING J, Hernandez G, Hartman L, Maksimovic J, et al
    Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial.
    Mult Scler. 2017 Oct 1:1352458517736377. doi: 10.1177/1352458517736377.
    PubMed     Abstract available


  430. BSTEH G, Hegen H, Teuchner B, Amprosi M, et al
    Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517740216. doi: 10.1177/1352458517740216.
    PubMed     Abstract available


  431. LEAVITT VM, Blanchard AR, Guo CY, Gelernt E, et al
    Aspirin is an effective pretreatment for exercise in multiple sclerosis: A double-blind randomized controlled pilot trial.
    Mult Scler. 2017 Oct 1:1352458517739138. doi: 10.1177/1352458517739138.
    PubMed     Abstract available


  432. DEKKER I, Sombekke MH, Witte BI, Geurts JJ, et al
    Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736147. doi: 10.1177/1352458517736147.
    PubMed     Abstract available


  433. BOESEN F, Norgaard M, Trenel P, Rasmussen PV, et al
    Longer term effectiveness of inpatient multidisciplinary rehabilitation on health-related quality of life in MS patients: a pragmatic randomized controlled trial - The Danish MS Hospitals Rehabilitation Study.
    Mult Scler. 2017 Oct 1:1352458517735188. doi: 10.1177/1352458517735188.
    PubMed     Abstract available


    September 2017
  434. TOBYNE SM, Ochoa WB, Bireley JD, Smith VM, et al
    Cognitive impairment and the regional distribution of cerebellar lesions in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517730132. doi: 10.1177/1352458517730132.
    PubMed     Abstract available


  435. FAZIA T, Pastorino R, Foco L, Han L, et al
    Investigating multiple sclerosis genetic susceptibility on the founder population of east-central Sardinia via association and linkage analysis of immune-related loci.
    Mult Scler. 2017 Sep 1:1352458517732841. doi: 10.1177/1352458517732841.
    PubMed     Abstract available


  436. HUPPKE P, Huppke B, Ellenberger D, Rostasy K, et al
    Therapy of highly active pediatric multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517732843. doi: 10.1177/1352458517732843.
    PubMed     Abstract available


  437. LANZILLO R, Cennamo G, Criscuolo C, Carotenuto A, et al
    Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517729463. doi: 10.1177/1352458517729463.
    PubMed     Abstract available


  438. COMBER L, Quinn G, McGuigan C, Galvin R, et al
    Medication usage and falls in people with multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517731912. doi: 10.1177/1352458517731912.
    PubMed     Abstract available


  439. MEINL I, Havla J, Hohlfeld R, Kumpfel T, et al
    Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517731913. doi: 10.1177/1352458517731913.
    PubMed     Abstract available


  440. GIOVANNONI G, Wiendl H, Turner B, Umans K, et al
    Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.
    Mult Scler. 2017 Sep 1:1352458517729464. doi: 10.1177/1352458517729464.
    PubMed     Abstract available


  441. KAPPOS L, Arnold DL, Bar-Or A, Camm AJ, et al
    Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517728343. doi: 10.1177/1352458517728343.
    PubMed     Abstract available


  442. BISECCO A, Nardo FD, Docimo R, Caiazzo G, et al
    Fatigue in multiple sclerosis: The contribution of resting-state functional connectivity reorganization.
    Mult Scler. 2017 Sep 1:1352458517730932. doi: 10.1177/1352458517730932.
    PubMed     Abstract available


  443. CHARVET LE, Dobbs B, Shaw MT, Bikson M, et al
    Remotely supervised transcranial direct current stimulation for the treatment of fatigue in multiple sclerosis: Results from a randomized, sham-controlled trial.
    Mult Scler. 2017 Sep 1:1352458517732842. doi: 10.1177/1352458517732842.
    PubMed     Abstract available


    August 2017
  444. BRUNDIN L, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Sweden.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  445. BATTAGLIA M, Kobelt G, Ponzio M, Berg J, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  446. BERGER T, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  447. DUBOIS B, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  448. OREJA-GUEVARA C, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  449. CALABRESE P, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  450. UITDEHAAG B, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  451. FLACHENECKER P, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  452. KOBELT G, Eriksson J, Phillips G, Berg J, et al
    The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  453. PENTEK M, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  454. BOYKO A, Kobelt G, Berg J, Boyko O, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  455. RASMUSSEN PV, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Denmark.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  456. LEBRUN-FRENAY C, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for France.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  457. THOMPSON A, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  458. SELMAJ K, Kobelt G, Berg J, Orlewska E, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  459. SA MJ, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  460. HAVRDOVA E, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  461. VERMOHLEN V, Schiller P, Schickendantz S, Drache M, et al
    Hippotherapy for patients with multiple sclerosis: A multicenter randomized controlled trial (MS-HIPPO).
    Mult Scler. 2017 Aug 1:1352458517721354. doi: 10.1177/1352458517721354.
    PubMed     Abstract available


  462. RUHRMANN S, Ewing E, Piket E, Kular L, et al
    Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes.
    Mult Scler. 2017 Aug 1:1352458517721356. doi: 10.1177/1352458517721356.
    PubMed     Abstract available


  463. LAROCCA NG, Hudson LD, Rudick R, Amtmann D, et al
    The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
    Mult Scler. 2017 Aug 1:1352458517723718. doi: 10.1177/1352458517723718.
    PubMed     Abstract available


  464. VAVASOUR IM, Huijskens SC, Li DK, Traboulsee AL, et al
    Global loss of myelin water over 5 years in multiple sclerosis normal-appearing white matter.
    Mult Scler. 2017 Aug 1:1352458517723717. doi: 10.1177/1352458517723717.
    PubMed     Abstract available


  465. BERGAMASCHI R, Cortese A, Pichiecchio A, Berzolari FG, et al
    Air pollution is associated to the multiple sclerosis inflammatory activity as measured by brain MRI.
    Mult Scler. 2017 Aug 1:1352458517726866. doi: 10.1177/1352458517726866.
    PubMed     Abstract available


  466. LOUAPRE C, Govindarajan ST, Gianni C, Madigan N, et al
    Heterogeneous pathological processes account for thalamic degeneration in multiple sclerosis: Insights from 7 T imaging.
    Mult Scler. 2017 Aug 1:1352458517726382. doi: 10.1177/1352458517726382.
    PubMed     Abstract available


  467. SELLEBJERG F, Bornsen L, Ammitzboll C, Nielsen JE, et al
    Defining active progressive multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517726592. doi: 10.1177/1352458517726592.
    PubMed     Abstract available


  468. ZIMMER P, Bloch W, Schenk A, Oberste M, et al
    High-intensity interval exercise improves cognitive performance and reduces matrix metalloproteinases-2 serum levels in persons with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2017 Aug 1:1352458517728342. doi: 10.1177/1352458517728342.
    PubMed     Abstract available


  469. SOLOMON AJ, Watts R, Ontaneda D, Absinta M, et al
    Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.
    Mult Scler. 2017 Aug 1:1352458517726383. doi: 10.1177/1352458517726383.
    PubMed     Abstract available


  470. AFOLABI D, Albor C, Zalewski L, Altmann DR, et al
    Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517726380. doi: 10.1177/1352458517726380.
    PubMed     Abstract available


  471. FAISSNER S, Mahjoub Y, Mishra M, Haupeltshofer S, et al
    Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?
    Mult Scler. 2017 Aug 1:1352458517728811. doi: 10.1177/1352458517728811.
    PubMed     Abstract available


  472. KALINCIK T, Jokubaitis V, Spelman T, Horakova D, et al
    Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517728812. doi: 10.1177/1352458517728812.
    PubMed     Abstract available


  473. BOVE R, Chitnis T, Cree BA, Tintore M, et al
    SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.
    Mult Scler. 2017 Aug 1:1352458517726657. doi: 10.1177/1352458517726657.
    PubMed     Abstract available


  474. GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan K, et al
    Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
    Mult Scler. 2017 Aug 1:1352458517727603. doi: 10.1177/1352458517727603.
    PubMed     Abstract available


  475. SEHR T, Proschmann U, Thomas K, Ziemssen T, et al
    Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".
    Mult Scler. 2017 Aug 1:1352458517726384. doi: 10.1177/1352458517726384.
    PubMed    


  476. LEURS CE, van Kempen ZL, Dekker I, Balk LJ, et al
    Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.
    Mult Scler. 2017 Aug 1:1352458517726381. doi: 10.1177/1352458517726381.
    PubMed     Abstract available


    July 2017
  477. MIGLIORE S, Curcio G, Couyoumdjian A, Ghazaryan A, et al
    Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol.
    Mult Scler. 2017 Jul 1:1352458517719149. doi: 10.1177/1352458517719149.
    PubMed     Abstract available


  478. KJOLHEDE T, Siemonsen S, Wenzel D, Stellmann JP, et al
    Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?
    Mult Scler. 2017 Jul 1:1352458517722645. doi: 10.1177/1352458517722645.
    PubMed     Abstract available


  479. TANAKA M, Kinoshita M, Tanaka K
    Intermittent drug holidays in fingolimod therapy for multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517722647. doi: 10.1177/1352458517722647.
    PubMed    


  480. STAMPANONI BASSI M, Leocani L, Comi G, Iezzi E, et al
    Can pharmacological manipulation of LTP favor the effects of motor rehabilitation in multiple sclerosis?
    Mult Scler. 2017 Jul 1:1352458517721358. doi: 10.1177/1352458517721358.
    PubMed     Abstract available


  481. ROLF L, Muris AH, Mathias A, Du Pasquier R, et al
    Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517722646. doi: 10.1177/1352458517722646.
    PubMed     Abstract available


  482. BALDASSARI LE, Salter AR, Longbrake EE, Cross AH, et al
    Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS.
    Mult Scler. 2017 Jul 1:1352458517721357. doi: 10.1177/1352458517721357.
    PubMed     Abstract available


  483. DUNN N, Juto A, Ryner M, Manouchehrinia A, et al
    Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
    Mult Scler. 2017 Jul 1:1352458517720044. doi: 10.1177/1352458517720044.
    PubMed     Abstract available


  484. CANCELLI A, Cottone C, Giordani A, Migliore S, et al
    Personalized, bilateral whole-body somatosensory cortex stimulation to relieve fatigue in multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517720528. doi: 10.1177/1352458517720528.
    PubMed     Abstract available


  485. RODRIGUEZ-LEAL FA, Haase R, Thomas K, Eisele JC, et al
    Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
    Mult Scler. 2017 Jul 1:1352458517720043. doi: 10.1177/1352458517720043.
    PubMed     Abstract available


    June 2017
  486. CHOI IY, Lee P, Adany P, Hughes AJ, et al
    In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517711568. doi: 10.1177/1352458517711568.
    PubMed     Abstract available


  487. SATTARNEZHAD N, Farrow S, Kimbrough D, Glanz B, et al
    Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients.
    Mult Scler. 2017 Jun 1:1352458517713667. doi: 10.1177/1352458517713667.
    PubMed     Abstract available


  488. LEE H, Nakamura K, Narayanan S, Brown R, et al
    Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517715811. doi: 10.1177/1352458517715811.
    PubMed     Abstract available


  489. BOESEN MS, Magyari M, Koch-Henriksen N, Thygesen LC, et al
    Pediatric-onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during 1977-2015: A nationwide population-based incidence study.
    Mult Scler. 2017 Jun 1:1352458517713669. doi: 10.1177/1352458517713669.
    PubMed     Abstract available


  490. PAKPOOR J, Seminatore B, Graves JS, Schreiner T, et al
    Dietary factors and pediatric multiple sclerosis: A case-control study.
    Mult Scler. 2017 Jun 1:1352458517713343. doi: 10.1177/1352458517713343.
    PubMed     Abstract available


  491. SALMEN A
    Clinical commentary on "Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab".
    Mult Scler. 2017 Jun 1:1352458517717810. doi: 10.1177/1352458517717810.
    PubMed    


  492. MULERO P, Auger C, Parolin L, Fonseca E, et al
    Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.
    Mult Scler. 2017 Jun 1:1352458517711569. doi: 10.1177/1352458517711569.
    PubMed     Abstract available


  493. FOLEY RW, Tagg NT, Schindler MK, Fenton KM, et al
    Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517702533. doi: 10.1177/1352458517702533.
    PubMed     Abstract available


  494. DOBRYAKOVA E, Hulst HE, Spirou A, Chiaravalloti ND, et al
    Fronto-striatal network activation leads to less fatigue in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717087. doi: 10.1177/1352458517717087.
    PubMed     Abstract available


  495. RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
    Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517719152. doi: 10.1177/1352458517719152.
    PubMed    


  496. YAP SM, McNicholas N, Hutchinson M, McGuigan C, et al
    Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis - Not always self-limiting, fully reversible or predictable.
    Mult Scler. 2017 Jun 1:1352458517719151. doi: 10.1177/1352458517719151.
    PubMed    


  497. WEYGANDT M, Wakonig K, Behrens J, Meyer-Arndt L, et al
    Brain activity, regional gray matter loss, and decision-making in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717089. doi: 10.1177/1352458517717089.
    PubMed     Abstract available


  498. HIDALGO DE LA CRUZ M, d'Ambrosio A, Valsasina P, Pagani E, et al
    Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717807. doi: 10.1177/1352458517717807.
    PubMed     Abstract available


  499. RUANO L, Branco M, Portaccio E, Goretti B, et al
    Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study.
    Mult Scler. 2017 Jun 1:1352458517717341. doi: 10.1177/1352458517717341.
    PubMed     Abstract available


  500. BOZ C, Terzi M, Zengin Karahan S, Sen S, et al
    Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717806. doi: 10.1177/1352458517717806.
    PubMed     Abstract available


    May 2017
  501. GOVEROVER Y, Chiaravalloti N, Genova H, DeLuca J, et al
    A randomized controlled trial to treat impaired learning and memory in multiple sclerosis: The self-GEN trial.
    Mult Scler. 2017 May 1:1352458517709955. doi: 10.1177/1352458517709955.
    PubMed     Abstract available


  502. BENEDICT RH, Cohan S, Lynch SG, Riester K, et al
    Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
    Mult Scler. 2017 May 1:1352458517707345. doi: 10.1177/1352458517707345.
    PubMed     Abstract available


  503. FREILICH J, Manouchehrinia A, Trusheim M, Baird LG, et al
    Characterization of annual disease progression of multiple sclerosis patients: A population-based study.
    Mult Scler. 2017 May 1:1352458517706252. doi: 10.1177/1352458517706252.
    PubMed     Abstract available


  504. ZEYDAN B, Lowe VJ, Schwarz CG, Przybelski SA, et al
    Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707346. doi: 10.1177/1352458517707346.
    PubMed     Abstract available


  505. SHINODA K, Matsushita T, Nakamura Y, Masaki K, et al
    HLA-DRB1*04:05 allele is associated with intracortical lesions on three-dimensional double inversion recovery images in Japanese patients with multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707067. doi: 10.1177/1352458517707067.
    PubMed     Abstract available


  506. SALTER A, Thomas NP, Tyry T, Cutter GR, et al
    A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.
    Mult Scler. 2017 May 1:1352458517711274. doi: 10.1177/1352458517711274.
    PubMed     Abstract available


  507. SUMOWSKI JF, Leavitt VM, Rocca MA, Inglese M, et al
    Mesial temporal lobe and subcortical grey matter volumes differentially predict memory across stages of multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517708873. doi: 10.1177/1352458517708873.
    PubMed     Abstract available


  508. CAWLEY N, Tur C, Prados F, Plantone D, et al
    Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517709954. doi: 10.1177/1352458517709954.
    PubMed     Abstract available


  509. BALK LJ, Coric D, Nij Bijvank JA, Killestein J, et al
    Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517708463. doi: 10.1177/1352458517708463.
    PubMed     Abstract available


  510. PRINEAS JW, Parratt JDE
    Multiple sclerosis: Serum anti-CNS autoantibodies.
    Mult Scler. 2017 May 1:1352458517706037. doi: 10.1177/1352458517706037.
    PubMed     Abstract available


  511. PALOTAI M, Mike A, Cavallari M, Strammer E, et al
    Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517711273. doi: 10.1177/1352458517711273.
    PubMed     Abstract available


  512. MARINO M, Frisullo G, Di Sante G, Samengo DM, et al
    Low reliability of anti-KIR4.183-120 peptide auto-antibodies in multiple sclerosis patients.
    Mult Scler. 2017 May 1:1352458517711275. doi: 10.1177/1352458517711275.
    PubMed     Abstract available


  513. REDONDO J, Sarkar P, Kemp K, Virgo PF, et al
    Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro.
    Mult Scler. 2017 May 1:1352458517711276. doi: 10.1177/1352458517711276.
    PubMed     Abstract available


  514. BIBERACHER V, Schmidt P, Selter RC, Pernpeinter V, et al
    Fatigue in multiple sclerosis: Associations with clinical, MRI and CSF parameters.
    Mult Scler. 2017 May 1:1352458517712078. doi: 10.1177/1352458517712078.
    PubMed     Abstract available


  515. SMOOT K, Spinelli KJ, Stuchiner T, Lucas L, et al
    Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
    Mult Scler. 2017 May 1:1352458517709956. doi: 10.1177/1352458517709956.
    PubMed     Abstract available


  516. TORTORELLA C, Direnzo V, Ruggieri M, Zoccolella S, et al
    Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517711774. doi: 10.1177/1352458517711774.
    PubMed     Abstract available


  517. VAN DER VUURST DE VRIES RM, van den Dorpel JJ, Mescheriakova JY, Runia TF, et al
    Fatigue after a first attack of suspected multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517709348. doi: 10.1177/1352458517709348.
    PubMed     Abstract available


  518. VAN DEN AKKER LE, Beckerman H, Collette EH, Twisk JW, et al
    Cognitive behavioral therapy positively affects fatigue in patients with multiple sclerosis: Results of a randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517709361. doi: 10.1177/1352458517709361.
    PubMed     Abstract available


  519. HEINE M, Verschuren O, Hoogervorst EL, van Munster E, et al
    Does aerobic training alleviate fatigue and improve societal participation in patients with multiple sclerosis? A randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517696596. doi: 10.1177/1352458517696596.
    PubMed     Abstract available


  520. BLIKMAN LJ, van Meeteren J, Twisk JW, de Laat FA, et al
    Effectiveness of energy conservation management on fatigue and participation in multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517702751. doi: 10.1177/1352458517702751.
    PubMed     Abstract available


  521. KAPPOS L, Butzkueven H, Wiendl H, Spelman T, et al
    Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
    Mult Scler. 2017 May 1:1352458517709619. doi: 10.1177/1352458517709619.
    PubMed     Abstract available


  522. SORMANI MP
    Why non-inferiority is more challenging than superiority?
    Mult Scler. 2017;23:790-791.
    PubMed     Abstract available


  523. HOEPNER R, Kolb EM, Dahlhaus S, Hellwig K, et al
    Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
    Mult Scler. 2017;23:830-835.
    PubMed     Abstract available


  524. PITTERI M, Romualdi C, Magliozzi R, Monaco S, et al
    Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study.
    Mult Scler. 2017;23:848-854.
    PubMed     Abstract available


  525. VAN KEMPEN ZL, Leurs CE, Witte BI, de Vries A, et al
    The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.
    Mult Scler. 2017 May 1:1352458517708464. doi: 10.1177/1352458517708464.
    PubMed     Abstract available


    April 2017
  526. COETZEE T, Thompson A
    When are we going to take modifiable risk factors more seriously in multiple sclerosis?
    Mult Scler. 2017;23:494-495.
    PubMed    


  527. AL-LOUZI O, Button J, Newsome SD, Calabresi PA, et al
    Retrograde trans-synaptic visual pathway degeneration in multiple sclerosis: A case series.
    Mult Scler. 2017 Apr 1:1352458516679035. doi: 10.1177/1352458516679035.
    PubMed     Abstract available


  528. SOLARI A, Giordano A, Patti F, Grasso MG, et al
    Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517704078. doi: 10.1177/1352458517704078.
    PubMed     Abstract available


  529. COHEN JA, Imrey PB, Planchon SM, Bermel RA, et al
    Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517703802. doi: 10.1177/1352458517703802.
    PubMed     Abstract available


  530. GIOVANNONI G, Tomic D, Bright JR, Havrdova E, et al
    "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517703193. doi: 10.1177/1352458517703193.
    PubMed     Abstract available


  531. MORANDI E, Tarlinton RE, Tanasescu R, Gran B, et al
    Human endogenous retroviruses and multiple sclerosis: Causation, association, or after-effect?
    Mult Scler. 2017 Apr 1:1352458517704711. doi: 10.1177/1352458517704711.
    PubMed     Abstract available


  532. KLAUSER AM, Wiebenga OT, Eijlers AJ, Schoonheim MM, et al
    Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517702534. doi: 10.1177/1352458517702534.
    PubMed     Abstract available


  533. AMATO MP
    The diagnostic dilemma of multiple sclerosis presenting with isolated cognitive and behavioral disorders.
    Mult Scler. 2017 Apr 1:1352458517705002. doi: 10.1177/1352458517705002.
    PubMed     Abstract available


  534. ZAMBON AA, Cecchetti G, Caso F, Santangelo R, et al
    Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case.
    Mult Scler. 2017 Apr 1:1352458517702550. doi: 10.1177/1352458517702550.
    PubMed     Abstract available


  535. CIAMPI E, Uribe-San-Martin R, Godoy-Santin J, Cruz JP, et al
    Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.
    Mult Scler. 2017 Apr 1:1352458517702968. doi: 10.1177/1352458517702968.
    PubMed     Abstract available


  536. POP R, Kipfer S
    Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517702535. doi: 10.1177/1352458517702535.
    PubMed     Abstract available


  537. PAREES I
    Clinical commentary on "Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis" and "Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients".
    Mult Scler. 2017 Apr 1:1352458517702555. doi: 10.1177/1352458517702555.
    PubMed     Abstract available


  538. BODINI B, Branzoli F, Poirion E, Garcia-Lorenzo D, et al
    Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy.
    Mult Scler. 2017 Apr 1:1352458517698249. doi: 10.1177/1352458517698249.
    PubMed     Abstract available


  539. KOLBER P, Droby A, Roebroeck A, Goebel R, et al
    A "kissing lesion": In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458516683267. doi: 10.1177/1352458516683267.
    PubMed     Abstract available


  540. KILSDONK ID, Schoonheim M, Wattjes MP
    In-vivo imaging of meningeal inflammation in multiple sclerosis: Presence of evidence or evidence of presence?
    Mult Scler. 2017 Apr 1:1352458517704924. doi: 10.1177/1352458517704924.
    PubMed    


  541. TOUSSAINT-DUYSTER LC, Wong YYM, Van der Cammen-van Zijp MH, Van Pelt-Gravesteijn D, et al
    Fatigue and physical functioning in children with multiple sclerosis and acute disseminated encephalomyelitis.
    Mult Scler. 2017 Apr 1:1352458517706038. doi: 10.1177/1352458517706038.
    PubMed     Abstract available


  542. HAGENS MH, Killestein J, Yaqub MM, van Dongen GA, et al
    Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study.
    Mult Scler. 2017 Apr 1:1352458517704507. doi: 10.1177/1352458517704507.
    PubMed     Abstract available


  543. SORMANI MP
    Indirect comparisons of treatment effects: Network meta-analyses.
    Mult Scler. 2017;23:510-512.
    PubMed     Abstract available


  544. BOUDOT DE LA MOTTE M, Louapre C, Bertrand A, Reach P, et al
    Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
    Mult Scler. 2017;23:614-616.
    PubMed     Abstract available


  545. AIRAS L, Rissanen E, Rinne J
    Imaging of microglial activation in MS using PET: Research use and potential future clinical application.
    Mult Scler. 2017;23:496-504.
    PubMed     Abstract available


  546. HUM S, Lapierre Y, Scott SC, Duquette P, et al
    Trajectory of MS disease course for men and women over three eras.
    Mult Scler. 2017;23:534-545.
    PubMed     Abstract available


  547. D'SOUZA M, Yaldizli O, John R, Vogt DR, et al
    Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study.
    Mult Scler. 2017;23:597-603.
    PubMed     Abstract available


  548. VERMERSCH P, Hobart J, Dive-Pouletty C, Bozzi S, et al
    Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?
    Mult Scler. 2017;23:604-613.
    PubMed     Abstract available


  549. CIAMPI E, Pareto D, Sastre-Garriga J, Vidal-Jordana A, et al
    Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
    Mult Scler. 2017;23:556-566.
    PubMed     Abstract available


  550. BROWNLEE WJ, Altmann DR, Alves Da Mota P, Swanton JK, et al
    Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome.
    Mult Scler. 2017;23:665-674.
    PubMed     Abstract available


  551. SORMANI MP, Kappos L, Radue EW, Cohen J, et al
    Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.
    Mult Scler. 2017;23:656-664.
    PubMed     Abstract available


  552. SIGNORI A, Izquierdo G, Lugaresi A, Hupperts R, et al
    Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
    Mult Scler. 2017 Apr 1:1352458517703800. doi: 10.1177/1352458517703800.
    PubMed     Abstract available


    March 2017
  553. BOGIE JF, Boelen E, Louagie E, Delputte P, et al
    CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517698759. doi: 10.1177/1352458517698759.
    PubMed     Abstract available


  554. PITAROKOILI K, Hellwig K, Lukas C, Gold R, et al
    Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.
    Mult Scler. 2017;23:483-486.
    PubMed     Abstract available


  555. ARRAMBIDE G
    Commentary on "Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis".
    Mult Scler. 2017;23:486-487.
    PubMed    


  556. MARRIE RA
    What is the risk of suicide in multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517699992. doi: 10.1177/1352458517699992.
    PubMed    


  557. KALSON-RAY S, Edan G, Leray E
    An excessive risk of suicide may no longer be a reality for multiple sclerosis patients.
    Mult Scler. 2017 Mar 1:1352458517699873. doi: 10.1177/1352458517699873.
    PubMed     Abstract available


  558. LEURS CE, Podlesniy P, Trullas R, Balk L, et al
    Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.
    Mult Scler. 2017 Mar 1:1352458517699874. doi: 10.1177/1352458517699874.
    PubMed     Abstract available


  559. ROCCA MA, Valsasina P, Leavitt VM, Rodegher M, et al
    Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment.
    Mult Scler. 2017 Mar 1:1352458517699875. doi: 10.1177/1352458517699875.
    PubMed     Abstract available


  560. RIO J, Rovira A, Tintore M, Otero-Romero S, et al
    Disability progression markers over 6-12 years in interferon-beta-treated multiple sclerosis patients.
    Mult Scler. 2017 Mar 1:1352458517698052. doi: 10.1177/1352458517698052.
    PubMed     Abstract available


  561. CORTESE M, Riise T, Bjornevik K, Myhr KM, et al
    Body size and physical exercise, and the risk of multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699289. doi: 10.1177/1352458517699289.
    PubMed     Abstract available


  562. RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
    Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699876. doi: 10.1177/1352458517699876.
    PubMed     Abstract available


  563. FEINSTEIN A, Pavisian B
    Multiple sclerosis and suicide.
    Mult Scler. 2017 Mar 1:1352458517702553. doi: 10.1177/1352458517702553.
    PubMed     Abstract available


  564. CHARVET LE, Shaw M, Frontario A, Langdon D, et al
    Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing.
    Mult Scler. 2017 Mar 1:1352458517701588. doi: 10.1177/1352458517701588.
    PubMed     Abstract available


  565. HOUTCHENS MK, Zapata LB, Curtis KM, Whiteman MK, et al
    Contraception for women with multiple sclerosis: Guidance for healthcare providers.
    Mult Scler. 2017 Mar 1:1352458517701314. doi: 10.1177/1352458517701314.
    PubMed     Abstract available


  566. RUGGIERI S, Fanelli F, Castelli L, Petsas N, et al
    Lesion symptom map of cognitive-postural interference in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517701313. doi: 10.1177/1352458517701313.
    PubMed     Abstract available


  567. TOURBAH A, Sedel F
    Reply to the letter: Biotinidase deficiency masquerading as multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517702554. doi: 10.1177/1352458517702554.
    PubMed    


  568. WOLF B
    Biotinidase deficiency masquerading as multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517702551. doi: 10.1177/1352458517702551.
    PubMed    


  569. GYLLENSTEN H, Wiberg M, Alexanderson K, Friberg E, et al
    Comparing costs of illness of multiple sclerosis in three different years: A population-based study.
    Mult Scler. 2017 Mar 1:1352458517702549. doi: 10.1177/1352458517702549.
    PubMed     Abstract available


  570. INEICHEN BV, Schneider MP, Hlavica M, Hagenbuch N, et al
    High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517703801. doi: 10.1177/1352458517703801.
    PubMed     Abstract available


  571. SORMANI MP
    Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts.
    Mult Scler. 2017;23:378-381.
    PubMed     Abstract available


  572. GRAVES JS, Chohan H, Cedars B, Arnow S, et al
    Sex differences and subclinical retinal injury in pediatric-onset MS.
    Mult Scler. 2017;23:447-455.
    PubMed     Abstract available


  573. YAP SM, McGuigan C
    High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.
    Mult Scler. 2017 Mar 1:1352458517697909. doi: 10.1177/1352458517697909.
    PubMed    


  574. ENZINGER C
    High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - NO.
    Mult Scler. 2017 Mar 1:1352458516681505. doi: 10.1177/1352458516681505.
    PubMed    


    February 2017
  575. HEMPEL S, Graham GD, Fu N, Estrada E, et al
    A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690271. doi: 10.1177/1352458517690271.
    PubMed     Abstract available


  576. HEMPEL S, Graham GD, Fu N, Estrada E, et al
    A systematic review of modifiable risk factors in the progression of multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690270. doi: 10.1177/1352458517690270.
    PubMed     Abstract available


  577. PRAVATA E, Rocca MA, Valsasina P, Riccitelli GC, et al
    Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692886. doi: 10.1177/1352458517692886.
    PubMed     Abstract available


  578. CARPENTER AF, Goodwin SJ, Bornstein PF, Larson AJ, et al
    Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
    Mult Scler. 2017;23:297-299.
    PubMed     Abstract available


  579. CAMERON MH, McMillan G
    Methylphenidate is likely less effective than placebo for improving imbalance, walking, and fatigue in people with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692421. doi: 10.1177/1352458517692421.
    PubMed    


  580. SONNENBERG A, Ajdacic-Gross V
    Similar birth-cohort patterns in Crohn's disease and multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517691620. doi: 10.1177/1352458517691620.
    PubMed     Abstract available


  581. BALCER LJ, Raynowska J, Nolan R, Galetta SL, et al
    Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690822. doi: 10.1177/1352458517690822.
    PubMed     Abstract available


  582. MOTL RW, Cohen JA, Benedict R, Phillips G, et al
    Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690823. doi: 10.1177/1352458517690823.
    PubMed     Abstract available


  583. BENEDICT RH, DeLuca J, Phillips G, LaRocca N, et al
    Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690821. doi: 10.1177/1352458517690821.
    PubMed     Abstract available


  584. FEYS P, Lamers I, Francis G, Benedict R, et al
    The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690824. doi: 10.1177/1352458517690824.
    PubMed     Abstract available


  585. HULST HE, Thompson AJ, Geurts JJ
    The measure tells the tale: Clinical outcome measures in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690825. doi: 10.1177/1352458517690825.
    PubMed    


  586. SHOR N, Amador MD, Dormont D, Lubetzki C, et al
    Involvement of peripheral III nerve in multiple sclerosis patient: Report of a new case and discussion of the underlying mechanism.
    Mult Scler. 2017 Feb 1:1352458516687401. doi: 10.1177/1352458516687401.
    PubMed     Abstract available


  587. ROVIRA A
    Peripheral nervous system involvement in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517693469. doi: 10.1177/1352458517693469.
    PubMed    


  588. CORIC D, Balk LJ, Verrijp M, Eijlers A, et al
    Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers.
    Mult Scler. 2017 Feb 1:1352458517694090. doi: 10.1177/1352458517694090.
    PubMed     Abstract available


  589. GIACOMINI E, Rizzo F, Etna MP, Cruciani M, et al
    Thymosin-alpha1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2017 Feb 1:1352458517695892. doi: 10.1177/1352458517695892.
    PubMed     Abstract available


  590. GALAZKA G, Mycko MP, Selmaj I, Raine CS, et al
    Multiple sclerosis: Serum-derived exosomes express myelin proteins.
    Mult Scler. 2017 Feb 1:1352458517696597. doi: 10.1177/1352458517696597.
    PubMed     Abstract available


  591. MAILLEUX J, Vanmierlo T, Bogie JF, Wouters E, et al
    Active liver X receptor signaling in phagocytes in multiple sclerosis lesions.
    Mult Scler. 2017 Feb 1:1352458517696595. doi: 10.1177/1352458517696595.
    PubMed     Abstract available


  592. ROY S, Drake AS, Eizaguirre MB, Zivadinov R, et al
    Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment?
    Mult Scler. 2017 Feb 1:1352458517695467. doi: 10.1177/1352458517695467.
    PubMed     Abstract available


  593. SCHWARTZ CE, Grover SA, Powell VE, Noguera A, et al
    Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517695469. doi: 10.1177/1352458517695469.
    PubMed     Abstract available


  594. CACAO G, Santos E, Martins Silva A
    Concurrent autoimmune hepatitis in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692885. doi: 10.1177/1352458517692885.
    PubMed     Abstract available


  595. GOLAN D, Doniger GM, Wissemann K, Zarif M, et al
    The impact of subjective cognitive fatigue and depression on cognitive function in patients with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517695470. doi: 10.1177/1352458517695470.
    PubMed     Abstract available


  596. ZECCA C, Merlini A, Disanto G, Rodegher M, et al
    Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
    Mult Scler. 2017 Feb 1:1352458517694089. doi: 10.1177/1352458517694089.
    PubMed     Abstract available


  597. KOBELT G, Thompson A, Berg J, Gannedahl M, et al
    New insights into the burden and costs of multiple sclerosis in Europe.
    Mult Scler. 2017 Feb 1:1352458517694432. doi: 10.1177/1352458517694432.
    PubMed     Abstract available


  598. WESNES K, Myhr KM, Riise T, Cortese M, et al
    Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study.
    Mult Scler. 2017 Feb 1:1352458517694088. doi: 10.1177/1352458517694088.
    PubMed     Abstract available


  599. PATEL VP, Walker LA, Feinstein A
    Revisiting cognitive reserve and cognition in multiple sclerosis: A closer look at depression.
    Mult Scler. 2017 Feb 1:1352458517692887. doi: 10.1177/1352458517692887.
    PubMed     Abstract available


  600. CLERICO M, De Mercanti S, Artusi CA, Durelli L, et al
    Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
    Mult Scler. 2017 Feb 1:1352458516688350. doi: 10.1177/1352458516688350.
    PubMed     Abstract available


  601. SHEIKH-TAHA M, Corman LC
    Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517694431. doi: 10.1177/1352458517694431.
    PubMed     Abstract available


  602. BACCHETTA F, Mathias A, Schluep M, Du Pasquier R, et al
    Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
    Mult Scler. 2017;23:300-303.
    PubMed     Abstract available


  603. SORMANI MP, Bruzzi P
    Estimating a treatment effect: Choosing between relative and absolute measures.
    Mult Scler. 2017;23:197-200.
    PubMed     Abstract available


  604. SORMANI MP, Muraro PA, Saccardi R, Mancardi G, et al
    NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
    Mult Scler. 2017;23:201-204.
    PubMed     Abstract available


    January 2017
  605. AMATO MP, Derfuss T, Hemmer B, Liblau R, et al
    Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.
    Mult Scler. 2017 Jan 6:1352458516686847. doi: 10.1177/1352458516686847.
    PubMed     Abstract available


  606. GONZALEZ TORRE JA, Cruz-Gomez AJ, Belenguer A, Sanchis-Segura C, et al
    Hippocampal dysfunction is associated with memory impairment in multiple sclerosis: A volumetric and functional connectivity study.
    Mult Scler. 2017 Jan 1:1352458516688349. doi: 10.1177/1352458516688349.
    PubMed     Abstract available


  607. MUNOZ MA, Kulick CG, Kortepeter CM, Levin RL, et al
    Liver injury associated with dimethyl fumarate in multiple sclerosis patients.
    Mult Scler. 2017 Jan 1:1352458516688351. doi: 10.1177/1352458516688351.
    PubMed     Abstract available


  608. MOTL RW, Mowry EM, Ehde DM, LaRocca NG, et al
    Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities.
    Mult Scler. 2017 Jan 1:1352458516687404. doi: 10.1177/1352458516687404.
    PubMed     Abstract available


  609. SUN H
    Temperature dependence of multiple sclerosis mortality rates in the United States.
    Mult Scler. 2017 Jan 1:1352458516688954. doi: 10.1177/1352458516688954.
    PubMed     Abstract available


  610. LEAVITT VM, Buyukturkoglu K, Inglese M, Sumowski JF, et al
    Protective personality traits: High openness and low neuroticism linked to better memory in multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458516685417. doi: 10.1177/1352458516685417.
    PubMed     Abstract available


  611. SONG J, Karrenbauer V, Manouchehrinia A, Almqvist C, et al
    Similar familial risk in multiple sclerosis subgroups.
    Mult Scler. 2017 Jan 1:1352458516684214. doi: 10.1177/1352458516684214.
    PubMed     Abstract available


  612. DE STEFANO N, Giorgio A, Battaglini M, De Leucio A, et al
    Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
    Mult Scler. 2017 Jan 1:1352458517690269. doi: 10.1177/1352458517690269.
    PubMed     Abstract available


  613. MA AY, Vitorino RC, Hojjat SP, Mulholland AD, et al
    The relationship between white matter fiber damage and gray matter perfusion in large-scale functionally defined networks in multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458517691149. doi: 10.1177/1352458517691149.
    PubMed     Abstract available


  614. BJORNEVIK K, Chitnis T, Ascherio A, Munger KL, et al
    Polyunsaturated fatty acids and the risk of multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458517691150. doi: 10.1177/1352458517691150.
    PubMed     Abstract available


  615. GOPAL S, Mikulskis A, Gold R, Fox RJ, et al
    Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
    Mult Scler. 2017 Jan 1:1352458517690617. doi: 10.1177/1352458517690617.
    PubMed     Abstract available


  616. MANOUCHEHRINIA A, Westerlind H, Kingwell E, Zhu F, et al
    Age Related Multiple Sclerosis Severity Score: Disability ranked by age.
    Mult Scler. 2017 Jan 1:1352458517690618. doi: 10.1177/1352458517690618.
    PubMed     Abstract available


  617. DECARD BF, Thone J, Haghikia A, Bornke C, et al
    Listeria rhombencephalitis mimicking a demyelinating event in an immunocompetent young patient.
    Mult Scler. 2017;23:123-125.
    PubMed     Abstract available


  618. LAROCHELLE C, Metz I, Lecuyer MA, Terouz S, et al
    Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal.
    Mult Scler. 2017;23:72-81.
    PubMed     Abstract available


  619. BURTON JM, Eliasziw M, Trufyn J, Tung C, et al
    A prospective cohort study of vitamin D in optic neuritis recovery.
    Mult Scler. 2017;23:82-93.
    PubMed     Abstract available


  620. HAAS J, Schneider K, Schwarz A, Korporal-Kuhnke M, et al
    Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
    Mult Scler. 2017;23:114-118.
    PubMed     Abstract available


  621. KALINCIK T, Sormani MP
    Reporting treatment outcomes in observational data: A fine balance.
    Mult Scler. 2017;23:21-22.
    PubMed     Abstract available


  622. SORMANI MP
    Subgroup analysis in MS trials.
    Mult Scler. 2017;23:34-35.
    PubMed     Abstract available


    December 2016
  623. MANOUCHEHRINIA A, Beiki O, Hillert J
    Clinical course of multiple sclerosis: A nationwide cohort study.
    Mult Scler. 2016 Dec 12. pii: 1352458516681197.
    PubMed     Abstract available


  624. BUDHRAM A, Parvathy S, Kremenchutzky M, Silverman M, et al
    Breaking down the gut microbiome composition in multiple sclerosis.
    Mult Scler. 2016 Dec 12. pii: 1352458516682105.
    PubMed     Abstract available


  625. KAPPOS L, Havrdova E, Giovannoni G, Khatri BO, et al
    No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
    Mult Scler. 2016 Dec 1:1352458516683266. doi: 10.1177/1352458516683266.
    PubMed     Abstract available


  626. CRISTOFANILLI M, Gratch D, Pagano B, McDermott K, et al
    Transglutaminase-6 is an autoantigen in progressive multiple sclerosis and is upregulated in reactive astrocytes.
    Mult Scler. 2016 Dec 1:1352458516684022. doi: 10.1177/1352458516684022.
    PubMed     Abstract available


  627. WIJNANDS JM, Kingwell E, Zhu F, Zhao Y, et al
    Infection-related health care utilization among people with and without multiple sclerosis.
    Mult Scler. 2016 Dec 1:1352458516681198. doi: 10.1177/1352458516681198.
    PubMed     Abstract available


  628. IKRAM MA, Vernooij MW, Roshchupkin GV, Hofman A, et al
    Genetic susceptibility to multiple sclerosis: Brain structure and cognitive function in the general population.
    Mult Scler. 2016 Dec 1:1352458516682104. doi: 10.1177/1352458516682104.
    PubMed     Abstract available


  629. BATISTA S, d'Almeida OC, Afonso A, Freitas S, et al
    Impairment of social cognition in multiple sclerosis: Amygdala atrophy is the main predictor.
    Mult Scler. 2016 Dec 1:1352458516680750. doi: 10.1177/1352458516680750.
    PubMed     Abstract available


  630. GHEZZI A
    Randomized clinical trials (RCTs) in pediatric multiple sclerosis: Are they really necessary?
    Mult Scler. 2016 Dec 1:1352458516684025. doi: 10.1177/1352458516684025.
    PubMed    


    November 2016
  631. GOLDMAN MD, Ward MD, Motl RW, Jones DE, et al
    Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale.
    Mult Scler. 2016 Nov 30. pii: 1352458516680749.
    PubMed     Abstract available


  632. HARRISON AM, das Nair R, Moss-Morris R
    Operationalising cognitive fatigability in multiple sclerosis: A Gordian knot that can be cut?
    Mult Scler. 2016 Nov 30. pii: 1352458516681862.
    PubMed     Abstract available


  633. SEPULVEDA M, Fernandez-Diez B, Martinez-Lapiscina EH, Llufriu S, et al
    Impairment of decision-making in multiple sclerosis: A neuroeconomic approach.
    Mult Scler. 2016 Nov 30. pii: 1352458516682103.
    PubMed     Abstract available


  634. DEVORAK J, Mokry LE, Morris JA, Forgetta V, et al
    Large differences in adiponectin levels have no clear effect on multiple sclerosis risk: A Mendelian randomization study.
    Mult Scler. 2016 Nov 30. pii: 1352458516681196.
    PubMed     Abstract available


  635. DATTA G, Violante IR, Scott G, Zimmerman K, et al
    Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis.
    Mult Scler. 2016 Nov 30. pii: 1352458516681504.
    PubMed     Abstract available


  636. VOORTMAN MM, Stojakovic T, Pirpamer L, Jehna M, et al
    Prognostic value of free light chains lambda and kappa in early multiple sclerosis.
    Mult Scler. 2016 Nov 29. pii: 1352458516681503.
    PubMed     Abstract available


  637. VENTURA RE, Antezana AO, Bacon T, Kister I, et al
    Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans.
    Mult Scler. 2016 Nov 29. pii: 1352458516679894.
    PubMed     Abstract available


  638. ROY S, Frndak S, Drake AS, Irwin L, et al
    Differential effects of aging on motor and cognitive functioning in multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516679036.
    PubMed     Abstract available


  639. VAN DIJK PA, Kirk-Brown AK, Taylor B, van der Mei I, et al
    Closing the gap: Longitudinal changes in employment for Australians with multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516678934.
    PubMed     Abstract available


  640. ARROYO GONZALEZ R, Kita M, Crayton H, Havrdova E, et al
    Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516677589.
    PubMed     Abstract available


  641. ABDOLLAHPOUR I, Nedjat S, Sahraian MA, Mansournia MA, et al
    Waterpipe smoking associated with multiple sclerosis: A population-based incident case-control study.
    Mult Scler. 2016 Nov 10. pii: 1352458516677867.
    PubMed     Abstract available


  642. CARLING A, Forsberg A, Gunnarsson M, Nilsagard Y, et al
    CoDuSe group exercise programme improves balance and reduces falls in people with multiple sclerosis: A multi-centre, randomized, controlled pilot study.
    Mult Scler. 2016 Nov 10. pii: 1352458516677591.
    PubMed     Abstract available


  643. SACCA F, Costabile T, Carotenuto A, Lanzillo R, et al
    The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests.
    Mult Scler. 2016 Nov 3. pii: 1352458516677592.
    PubMed     Abstract available


  644. MIKOLAJCZAK J, Zimmermann H, Kheirkhah A, Kadas EM, et al
    Patients with multiple sclerosis demonstrate reduced subbasal corneal nerve fibre density.
    Mult Scler. 2016 Nov 3. pii: 1352458516677590.
    PubMed     Abstract available


  645. CHATAWAY J
    Biotin in progressive multiple sclerosis: A new lead?
    Mult Scler. 2016;22:1640-1641.
    PubMed    


  646. GABILONDO I, Rilo O, Ojeda N, Pena J, et al
    The influence of posterior visual pathway damage on visual information processing speed in multiple sclerosis.
    Mult Scler. 2016 Nov 1:1352458516676642. doi: 10.1177/1352458516676642.
    PubMed     Abstract available


  647. CARUANA P, Lemmert K, Ribbons K, Lea R, et al
    Natural killer cell subpopulations are associated with MRI activity in a relapsing-remitting multiple sclerosis patient cohort from Australia.
    Mult Scler. 2016 Nov 1:1352458516679267. doi: 10.1177/1352458516679267.
    PubMed     Abstract available


    October 2016
  648. PLANCHE V, Ruet A, Coupe P, Lamargue-Hamel D, et al
    Hippocampal microstructural damage correlates with memory impairment in clinically isolated syndrome suggestive of multiple sclerosis.
    Mult Scler. 2016 Oct 25. pii: 1352458516675750.
    PubMed     Abstract available


  649. BSTEH G, Feige J, Ehling R, Auer M, et al
    Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.
    Mult Scler. 2016 Oct 20. pii: 1352458516675751.
    PubMed     Abstract available


  650. D'AMBROSIO A, Pagani E, Riccitelli GC, Colombo B, et al
    Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis.
    Mult Scler. 2016 Oct 19. pii: 1352458516674567.
    PubMed     Abstract available


  651. KAVALIUNAS A, Manouchehrinia A, Stawiarz L, Ramanujam R, et al
    Importance of early treatment initiation in the clinical course of multiple sclerosis.
    Mult Scler. 2016 Oct 17. pii: 1352458516675039.
    PubMed     Abstract available


  652. PIETROBONI AM, Schiano di Cola F, Scarioni M, Fenoglio C, et al
    CSF beta-amyloid as a putative biomarker of disease progression in multiple sclerosis.
    Mult Scler. 2016 Oct 17. pii: 1352458516674566.
    PubMed     Abstract available


  653. RUANO L, Portaccio E, Goretti B, Niccolai C, et al
    Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes.
    Mult Scler. 2016 Oct 13. pii: 1352458516674367.
    PubMed     Abstract available


  654. WICKSTROM A, Fagerstrom M, Wickstrom L, Granasen G, et al
    The impact of adjusted work conditions and disease-modifying drugs on work ability in multiple sclerosis.
    Mult Scler. 2016 Oct 6. pii: 1352458516671818.
    PubMed     Abstract available


  655. AHMAD H, Taylor BV, van der Mei I, Colman S, et al
    The impact of multiple sclerosis severity on health state utility values: Evidence from Australia.
    Mult Scler. 2016 Oct 3. pii: 1352458516672014.
    PubMed     Abstract available


  656. LUBRINI G, Rios Lago M, Perianez JA, Tallon Barranco A, et al
    The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis.
    Mult Scler. 2016;22:1607-1615.
    PubMed     Abstract available


  657. ARNETT P
    Lubrini et al.'s study, "The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis".
    Mult Scler. 2016;22:1512-1513.
    PubMed    


    September 2016
  658. MOBERG JY, Laursen B, Koch-Henriksen N, Thygesen LC, et al
    Employment, disability pension and income for children with parental multiple sclerosis.
    Mult Scler. 2016 Sep 28. pii: 1352458516672016.
    PubMed     Abstract available


  659. BOESCHOTEN RE, Dekker J, Uitdehaag BM, Beekman AT, et al
    Internet-based treatment for depression in multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2016 Sep 28. pii: 1352458516671820.
    PubMed     Abstract available


  660. RIBBONS K, Lea R, Tiedeman C, Mackenzie L, et al
    Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: A 50-year study.
    Mult Scler. 2016 Sep 28. pii: 1352458516671819.
    PubMed     Abstract available


  661. SCHLEMM L, Chien C, Bellmann-Strobl J, Dorr J, et al
    Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients.
    Mult Scler. 2016 Sep 27. pii: 1352458516670738.
    PubMed     Abstract available


  662. GAFSON A, Craner MJ, Matthews PM
    Personalised medicine for multiple sclerosis care.
    Mult Scler. 2016 Sep 26. pii: 1352458516672017.
    PubMed     Abstract available


  663. BJORNEVIK K, Riise T, Bostrom I, Casetta L, et al
    Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study.
    Mult Scler. 2016 Sep 23. pii: 1352458516671028.
    PubMed     Abstract available


  664. COLLIGAN E, Metzler A, Tiryaki E
    Shared decision-making in multiple sclerosis: A review.
    Mult Scler. 2016 Sep 23. pii: 1352458516671204.
    PubMed     Abstract available


  665. HENGSTMAN GJ
    Controversies in MS: All relapsing multiple sclerosis patients should be managed at a specialist clinic - Combine the best of two worlds!
    Mult Scler. 2016 Sep 21. pii: 1352458516670737.
    PubMed    


  666. LANDFELDT E, Castelo-Branco A, Svedbom A, Lofroth E, et al
    Sick leave and disability pension before and after diagnosis of multiple sclerosis.
    Mult Scler. 2016 Sep 20. pii: 1352458516667567.
    PubMed     Abstract available


  667. CHOI IY, Lee P, Hughes AJ, Denney DR, et al
    Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis.
    Mult Scler. 2016 Sep 12. pii: 1352458516669441.
    PubMed     Abstract available


  668. ORPEZ-ZAFRA T, Pavia J, Hurtado-Guerrero I, Pinto-Medel MJ, et al
    Decreased soluble IFN-beta receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.
    Mult Scler. 2016 Sep 9. pii: 1352458516667564.
    PubMed     Abstract available


  669. HAKOBYAN S, Luppe S, Evans DR, Harding K, et al
    Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.
    Mult Scler. 2016 Sep 9. pii: 1352458516669002.
    PubMed     Abstract available


  670. NELSON F, Akhtar MA, Zuniga E, Perez CA, et al
    Novel fMRI working memory paradigm accurately detects cognitive impairment in multiple sclerosis.
    Mult Scler. 2016 Sep 9. pii: 1352458516666186.
    PubMed     Abstract available


    August 2016
  671. VERMERSCH P, Smets L, Gold R
    Conclusions: Calls to action for improving the life of MS patients and their families.
    Mult Scler. 2016;22.
    PubMed     Abstract available


  672. VERMERSCH P, Faller A, Czarnota-Szalkowska D, Meesen B, et al
    The patient's perspective: How to create awareness for improving access to care and treatment of MS patients?
    Mult Scler. 2016;22.
    PubMed     Abstract available


    May 2016
  673. UHER T, Havrdova E, Sobisek L, Krasensky J, et al
    Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?
    Mult Scler. 2016 May 26. pii: 1352458516650525.
    PubMed     Abstract available


    April 2016
  674. MODVIG S, Degn M, Sander B, Horwitz H, et al
    Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis.
    Mult Scler. 2016;22:590-8.
    PubMed     Abstract available


  675. HADHOUM N, Hodel J, Defoort-Dhellemmes S, Duhamel A, et al
    Length of optic nerve double inversion recovery hypersignal is associated with retinal axonal loss.
    Mult Scler. 2016;22:649-58.
    PubMed     Abstract available


  676. NEMECEK A, Zimmermann H, Rubenthaler J, Fleischer V, et al
    Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression.
    Mult Scler. 2016;22:483-93.
    PubMed     Abstract available


    March 2016
  677. BEVER CT JR, Wallin MT
    Tribute to John F. Kurtzke, MD, FACP, FAAN: 1926-2015.
    Mult Scler. 2016;22:267-8.
    PubMed    


  678. ENZINGER C, Pinter D, Rocca MA, De Luca J, et al
    Longitudinal fMRI studies: Exploring brain plasticity and repair in MS.
    Mult Scler. 2016;22:269-78.
    PubMed     Abstract available


  679. PEKCEVIK Y, Mitchell CH, Mealy MA, Orman G, et al
    Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.
    Mult Scler. 2016;22:302-11.
    PubMed     Abstract available


  680. MAKHANI N, Banwell B, Tellier R, Yea C, et al
    Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination.
    Mult Scler. 2016;22:385-8.
    PubMed     Abstract available


  681. VAN SCHEPENDOM J, Gielen J, Laton J, Nagels G, et al
    Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail.
    Mult Scler. 2016;22:389-92.
    PubMed     Abstract available


    February 2016
  682. JARIUS S, Metz I, Konig FB, Ruprecht K, et al
    Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case.
    Mult Scler. 2016 Feb 11. pii: 1352458515622986.
    PubMed     Abstract available


  683. BERGAMASCHI R, Montomoli C
    Modeling the course and outcomes of MS is statistical twaddle--No.
    Mult Scler. 2016;22:142-4.
    PubMed    


  684. BEAUCHEMIN P, Carruthers R
    MS arising during Tocilizumab therapy for rheumatoid arthritis.
    Mult Scler. 2016;22:254-6.
    PubMed     Abstract available


  685. FERNANDEZ-CARBONELL C, Vargas-Lowy D, Musallam A, Healy B, et al
    Clinical and MRI phenotype of children with MOG antibodies.
    Mult Scler. 2016;22:174-84.
    PubMed     Abstract available


  686. HUPPERTS R, Lycke J, Short C, Gasperini C, et al
    Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
    Mult Scler. 2016;22:212-21.
    PubMed     Abstract available


    January 2016
  687. SASTRE-GARRIGA J, Wiendl H
    Highlights from the 31st ECTRIMS congress - Barcelona 2015.
    Mult Scler. 2016;22:7-10.
    PubMed    


  688. REINGOLD SC, Lublin FD
    William Austin Sibley, MD (1925-2015).
    Mult Scler. 2016;22:11-2.
    PubMed    


  689. FREEDMAN MS
    Are we in need of NEDA?
    Mult Scler. 2016;22:5-6.
    PubMed    


  690. ZAJDA M, Kazmierczak B, Zakrzewska-Pniewska B
    Aquaporin-4: A novel diagnostic biomarker for seronegative neuromyelitis optica.
    Mult Scler. 2016;22:125-6.
    PubMed    


    November 2015
  691. WATTJES MP, Wijburg MT, Vennegoor A, Witte BI, et al
    Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
    Mult Scler. 2015 Nov 12. pii: 1352458515615225.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: